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Abstract: Emergence of drug-resistant viral strains is one of the major milestones and the main
cause for the failure of antiretroviral therapy. Combination of different anti-HIV agents has
become the standard clinical practice to keep the viral load at low or even undetectable levels
and to prevent emergence of virus-drug resistance. Among the human immunodeficiency virus
(HIV) reverse transcriptase (RT) inhibitors, the so called nonnucleoside RT inhibitors
(NNRTIs) have gained a definitive place in the treatment of HIV infections in combination with nucleoside analogue RT
inhibitors (NRTIs) and HIV protease inhibitors (PIs). The virus can be markedly suppressed for a relatively long period of
time when exposed to multiple drug combination therapy (highly active antiretroviral therapy, HAART). TSAO
derivatives are a peculiar group of highly functionalized nucleosides that belong to the so-called nonnucleoside RT
inhibitors (NNRTIs). They exert their unique selectivity for HIV-1 through a specific interaction with the p51 subunit of
HIV-1 RT. They are the first small molecules that seem to interfere with the dimerization process of the enzyme. This
review covers the work carried out with this unique class of specific inhibitors of HIV-1 reverse transcriptase, including
structure activity relationship studies (SAR), its mechanism of action, resistance studies, model of interaction with the
enzyme, etc.
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INTRODUCTION
There is no doubt that the eradication or efficient control
of the AIDS epidemic is still one of the most important
challenges at the start of the 21st century. Although there is
currently no cure for AIDS, a variety of drugs are available
for treatment of the Human immunodeficiency virus type
(HIV) infection. To date, six nucleoside reverse transcriptase
(RT) inhibitors (NRTIs), one nucleotide reverse transcriptase
inhibitor (NtRTI), three nonnucleoside RT inhibitors
(NNRTIs), four protease inhibitors and recently a fusion
inhibitor are approved for treatment of AIDS [1-9]. A
number of other RT inhibitors, protease inhibitors but also
drugs targetting other sites of the virus replication cycle, are
currently subject of clinical trials [10,11].
Reverse Transcriptase (RT) is a key enzyme in the life
cycle of HIV which is responsible for the conversion of
genomic viral RNA into double-stranded proviral DNA, a
crucial step in the replication cycle of HIV [12, 13]. HIV RT
is an asymmetric heterodimer consisting of two subunits, p66
and p51 [14]. Crystal structures of unliganded RT [15], RT-
DNA complexes [16], and RT-inhibitor complexes [17] have
consistently shown that, despite the amino acid identity in
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both subunits, the polymerase subdomains (called fingers,
palm, thumb, and connection) are arranged differently in
each one, with p66 forming a large active-site cleft and p51
forming an inactive closed structure that provides structural
support to the polymerase domain of p66 [18-20]. The
catalytic site (located at this subunit) where polymerization
occurs contains a triad of aspartic acid residues at positions
110, 185 and 186 [21]. At least two Mg2+ ions may assist
with polymerization by binding to the carboxyl groups of
these aspartic acids [22,23]. The RT heterodimer represents
the biologically active form of the enzyme, while the
monomeric subunits have only low catalytic activity [24].
Indeed the p66 and p51 monomers are catalytically virtually
inert and it is only through dimer formation that enzymatic
activity is restored [24]. For the process of native
dimerization a two-step model has been proposed in which
the dimers are in equilibrium with the folded inactive
monomers [25]. The first step is a concentration-dependent
association of p66 and p51 that yields an inactive
intermediate that slowly isomerizes to the "mature"
heterodimeric form of the enzyme [26].
Several classes of RT inhibitors have been developed:
1. The nucleoside RT inhibitors (NRTIs)
They, upon metabolic activation (phosphorylation by
cellular kinases to their 5'-triphosphate forms), bind at the
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polymerase active site (the substrate-binding site) of RT [1,
27], acting then either as competitive substrates/inhibitors
with respect to the natural substrates (dNTPs) and/or as DNA
chain terminators [27]. Six nucleoside analogues have been
officially approved for clinical use as anti-HIV drugs "Fig.
(1)" zidovudine (AZT), zalcitabine (ddC), didanosine (ddI),
stavudine (d4T), lamivudine (3TC), and abacavir (ABC) [4,
8]. These drugs show important clinical benefits, but also
have important drawbacks including development of
resistance and severe dose-limiting toxic side effects, mostly
due to interaction with cellular DNA polymerases and/or
interference with nucleotide pools [1].
Fig. (1). Structures of approved nucleoside RT inhibitors (NRTIs).
2. The nucleotide RT inhibitors (NtRTIs) [acyclic
nucleoside phosphonates (ANPs)]
Adefovir (PMEA) and tenofovir (PMPA) "Fig. (2)", are
members of this class of potent and selective inhibitors of
HIV RT. These compounds are converted to their active
(diphosphorylated) metabolites by cellular enzymes. These
metabolites are potent inhibitors of HIV RT which act upon
incorporation into the growing viral DNA chain as DNA
chain terminators [1, 27]. Thus their mechanism of
antiretroviral action is virtually similar to that of NRTIs such
as AZT and ABC. They are resistant to catabolic degradation
such as dephosphorylation, due to the presence in their
stucture of the phosphonate group (isopolar with respect to
the phosphate). Oral prodrug forms of adefovir as adefovir
dipivoxil [Bis(POM)PMEA] and tenofovir as tenofovir
disoproxyl fumarate [Bis(POC)PMPA] "Fig. (2)", have been
used in clinical trials [28]. Tenofovir disoproxyl fumarate
has recently been approved for the treatment of HIV
infections and adefovir dipivoxil for HBV infections.
3. The nonnucleoside RT inhibitors (NNRTIs)
To this important class of RT inhibitors belong
nevirapine, delavirdine and efavirenz "Fig. (3)". They are
approved for the clinical treatment of HIV-1 infection in
combination with NRTIs and/or protease inhibitors [6-9].
NNRTIs are structurally diverse (more than 30 different
classes have been described) but they all are targeted
exclusively at the HIV-1 RT at an allosteric, non-substrate
binding site ("hydrophobic pocket") that is close (on average,
» 15Å) but distinct from the substrate binding site (NRTI-
binding site). This "pocket" does not exist in ligand-free RT,
and has not been reported in RTs other than HIV-1 RT [16a,
29-31]. NNRTIs do not need to be metabolically activated
and are noncompetitive with respect to both substrate and the
template/primer [1, 27].
Crystal structures of RT/NNRTI complexes revealed that,
upon binding of an NNRTI with the HIV-1 RT, the
template/primer undergoes a repositioning in the protein,
leading to a displacement of the binding groove by
approximately 2 Å away from the active binding site. This,
in turn, results in a markedly decreased enzyme activity in
the presence of the NNRTI. Thus, NNRTIs inhibit the HIV-1
RT enzyme due to distortion of the polymerase-active site, a
conclusion that has been supported by both structural [32]
and kinetic [33] studies. NNRTIs are highly potent and
specific inhibitors of HIV-1 replication [5, 7, 8]. They do not
inhibit the transcriptases of other lentiviruses including HIV-
2, Simian immunodeficiency virus (SIV) and Feline
immunodeficiency viruse (FIV) or other (retro)viruses.
TSAO DERIVATIVES: A UNIQUE CLASS OF
NNRTIS
Within the NNRTIs TSAO compounds represent a
unique family of antiretroviral compounds first described in
the early 90's by our research groups at the CSIC (Madrid,
Spain) and the Rega Institute (Leuven, Belgium) [34-36].
TSAO are highly functionalised nucleosides, being this the
first feature of their "uniqueness". However, mechanistically,
TSAO compounds behave as all the other NNRTIs,
inhibiting HIV-1 replication, but not the replication of HIV-2
or of other (retro)viruses [34a, 35a]. They are targeted at
HIV-1 reverse transcriptase at a nonsubstrate binding site.
They do not inhibit other DNA polymerases such as the
cellular DNA polymerases a, b, g and HSV-1 (herpes
simplex virus type 1) DNA polymerase [37, 38]. TSAO
compounds are relatively nontoxic to human cells; however,
like the other NNRTIs; they select for highly resistant HIV-1
strains [39, 40].
The prototype compound of this family is the [1-[2',5'-
bis-O-(tert  - butyldimethylsilyl) - b-D-ribofuranosyl]thymine]-
3'-spiro-5"-(4"-amino-1",2"-oxathiole-2",2"-dioxide) named
as TSAO-T "Fig. (3)" [34b]. TSAO-T is endowed with
potent anti-HIV-1 activity, that is not dependent on the cell
line (EC50: 0.017-0.058 mM) [34a]. TSAO-T inhibits
noncompetitively RT when poly(C) • oligo(dG) is used as
the template/primer and dGTP as the natural substrate [37a,
38]. No marked inhibitory effect is noted with other artificial
templates. In contrast, the other NNRTIs usually inhibit
HIV-1 RT in the presence of various template/primers,
although they usually prefer poly(C) • oligo(dG) as the
template/primer for optimal inhibition.
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SAR Studies in the TSAO Compounds
Since we first synthesized TSAO-T in 1992 [34], several
modifications have been carried out on this family of
compounds that have helped to reveal the structural
requirements of TSAO derivatives for their optimal
interaction with the HIV-1 RT.
In contrast to other NNRTIs this family of compounds
must fulfill a strict nucleosidic nature, that is, an intact ribose
moiety with very stringent structural requirements. Thus, all
TSAO derivatives need the concomitant presence in their
molecules of a 3'-spiro-5"-(4"-amino-1",2"-oxathiole-2",2"-
dioxide) moiety and tert-butyldimethylsilyl (TBDMS)
groups at both 2' and 5' positions of the sugar moiety, in
Fig. (2). Structures of acyclic nucleoside phosphonates (ANPs).
Fig. (3). Structures of nonnucleoside RT inhibitors (NNRTIs).
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nucleosides of ribo configuration, as a prerequisite for
antiviral activity [34, 41]. The corresponding xylo isomers
were devoid of any antiviral activity [42]. Change of the 3'-
spiro moiety to the 2' position of the ribose, resulted in
annihiliation of the antiviral activity. Removal of the
lipophilic (TBDMS) groups, either at 2', at 5' or at both
positions, gave inactive TSAO derivatives at subtoxic
concentrations (EC50: 30-1000 m M) [34b]. The corres-
ponding 2'- or 5'-deoxy analogues were also inactive.
Replacement of the 2'-TBDMS by other groups mimicking
either the lipophilic or the steric properties of TBDMS led to
TSAO compounds with 2- to 20-fold reduced anti-HIV-1
activity [43a], while a similar replacement at the 5'-position
rendered antivirally inactive TSAO compounds, thus,
pointing to a more critical role of the 5'-substituent for
activity. The only group that restored some activity (although
drastically reduced) is the tert-hexyldimethylsilyl group
(EC50: 0.8-2.0 m M) [43b].
In contrast, the base part of TSAO molecules is less
stringent in its structural requirements, but seems to play a
modulatory role of the activity/cytoxicity of the TSAO
compounds. The thymine of the prototype TSAO-T can be
considerably changed without compromising the anti-HIV-1
activity. It has been replaced by a number of other
pyrimidines (i.e. uracil, 5-ethyluracil, cytosine, 5-methyl-
cytosine, 5-substituted pyrimidines, etc), purines (adenine,
hypoxanthine, xanthine, etc) or several 4- and /or 5-
substituted-1,2,3-triazoles [34-36a, 37b, 37c, 44-46]. These
base-modified TSAO derivatives showed potent anti-HIV-1
activities. In general, the TSAO-purine derivatives were 3- to
5- fold less potent than the most active TSAO-pyrimidines or
TSAO-1,2,3-triazoles. Interestingly, alkyl or alkenyl
substitutions at the N-3 position of TSAO-pyrimidines or at
the N-1 position of TSAO-purines attenuated cytotoxicity
(10- to 20- fold), without affecting the anti-HIV-1 activity
[34-36a, 37b, 37c, 44, 45], resulting in compounds with
higher selectivity indices (SI = CC50/EC50). As an example
TSAO-m3T "Fig. (3)", the N-3-methyl analogue of TSAO-T,
showed a 20-fold higher SI than that of TSAO-T (SITSAO-m3T:
4088 vs SI TSAO-T: 227). It should be pointed out that further
modifications carried out at position N-3 of the thymine base
in the prototype compound TSAO-T, led to novel analogues
bearing at their N-3 position different amino acids (i.e. Ala,
Val, Asp and Glu) with unprotected carboxylic functions at
that position "Fig. (4)" [47]. Although, none of these new
analogues showed an improved activity/toxicity profile
(EC50: 0.05-10 m M; CC50: >250 m M) with respect to that of
TSAO-T or TSAO-m3T, they gained an interesting activity
against HIV-2 (EC50: 25-140 m M). These new TSAO lead
compounds should be further pursued to develop TSAO
molecules with greater potency and broader spectrum of
anti-HIV activity.
Several members among the TSAO-substituted triazoles
showed potent anti-HIV-1 activity comparable to that of the
TSAO prototype (TSAO-T). Thus, the 5-substituted amido-,
methylamido-, and dimethylamido-1,2-3-triazole derivatives
"Fig. (4)" showed potent anti-HIV-1 activity (EC50: 0.056-
0.52 m M). In particular, the 5-dimethylamido-1,2-3-triazole
TSAO derivative (9) emerged as the most active triazole
TSAO compound [46]. This was considered as a novel lead
to develop further TSAO derivatives with potent anti-HIV-1
activity, and new series of analogues possessing different
hydrocarbon shapes capping the amide at C-5 were prepared
[48]. Several of these new compounds showed not only
potent anti-HIV-1 activities but also a decreased or no
cytotoxicity which resulted in more selective compounds
than that of the parent TSAO-triazole prototype (9), as in the
case of 10 and 11. (SI10: 1470; SI11: 1190 vs SI9: 333).
Further studies aimed at gaining deeper insights into the
role that the thymine base of TSAO-T may play in the
interaction of TSAO compounds with HIV-1 RT, were
conducted. In particular, these studies were directed to assess
the role that aromaticity and different fragments mimicking
parts or the whole thymine base of TSAO-T may play in the
above mentioned interaction with the RT enzyme. Thus, in
1998 we reported on the synthesis and anti-HIV-1 activity of
a series of 3-spiro sugar derivatives. These compounds were
substituted at the anomeric position with non aromatic rings
Fig. (4). Structures of base modified TSAO-T derivatives (3-6) and TSAO-triazole derivatives (7-11).
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or with amine, amide, urea or thiourea moieties, derived
from a systematic disassemblage of the molecular
architecture of the thymine ring that mimic parts or the
whole thymine base of TSAO-T [49]. Also, a dihydrouracil-
TSAO analogue and O-glycosyl 3-spiro sugar derivatives
substituted at the anomeric position with aromatic and
nonaromatic lipophilic moieties (i.e. methyloxy or benzyloxy
groups) were prepared. Compounds substituted at the
anomeric position with an azido, amino or methoxy group,
respectively, were devoid of marked antiviral activity
(EC50:10-200 m M). However, the substituted urea sugar
derivatives led to an increase in antiviral potency (EC50:
0.35-4 m M). Among them are those urea derivatives that
mimic most closely the intact TSAO-T molecule (12-14)
"Fig. (5)" retained the highest antiviral activity. Also, the
dihydro-uracil TSAO derivative (15) retained pronounced
anti-HIV-1 activity. None of the compounds showed any
anti-HIV-2 activity. These abasic TSAO derivatives
represent the first examples of sugar derivatives that interact
in a specific manner with HIV-1 RT [49]. Urea derivatives,
which can mimic to a large extent both the shape and the
electrostatic potential of the thymine ring, can effectively
replace this nucleic acid base when incorporated into a
TSAO molecular framework with only moderate loss of
activity. The abasic TSAO analogue (14) is just one order of
magnitude less active than the prototype TSAO-T, and our
calculations suggest that this may be due to the energy
penalty involved in breaking the intramolecular hydrogen
bond in order to adopt a suitable conformation for binding
into the enzyme.
Fig. (5). Examples of abasic TSAO derivatives (12-14) and 5,6-
dihydrouracil-TSAO (15).
Our experimental data on TSAO derivatives strongly
suggest a specific interaction of the amino group of the 3'-
spiro moiety of TSAO molecules with the carboxylic group
of a glutamic acid residue at position 138 of the p51 subunit
of HIV-1 RT [18, 39, 40, 50,51]. This residue is located at
the top of the finger domain of the p51 subunit of HIV-1 RT,
that is part of the binding pocket of the HIV-1-specific RT
inhibitors at the p66 subunit [16a, 30, 31].
The 3'-spiro moiety of TSAO derivatives was replaced by
other 3'-spiro rings like 4-amino-2-oxazolone (16) or 4-
amino-1,2,3-oxathiazole-2,2-dioxide (17) "Fig. (6)" that
maintain a NH2 group at the same position as the 4"-NH2
group in the prototype compound TSAO-T, to allow the
specific interaction of these new TSAO analogues with the
carboxylic group of glutamic acid 138 of HIV-1 RT [52].
However, such replacements resulted in a decrease in the
anti-HIV-1 activity by two orders of magnitude (EC50, 16:
5.3-13 m M and EC50, 17: 5.3 m M vs EC50,TSAO-T: 0.04-0.06
m M), in spite of the fact that these novel TSAO analogues
fullfilled the structural requirements of the TSAO family for
activity. From comparative NMR studies, no significant
conformational differences were detected in solution
between TSAO-m3T and these new spiro analogues that may
account for the differences observed in their inhibitory
activity against HIV-1 RT. Comparative studies based on
theoretical calculations of the hydrophobicity, the solvation
free energies and molecular electrostatic potentials (MEP) of
the three spiro rings (aminooxathioledioxide, amino-
oxazolone and amino-1,2,3-oxathiazoledioxide) showed that
the calculated hydrophobicity (log P) values, dipole
moments and the electrostatic contributions to the solvation
free energies of the three spiro ring systems were also similar
[53]. However, the differences found in the calculated MEPs
of the spiro systems between TSAO-m3T and its analogues
suggest that the different electrostatic surroundings of the 4"-
amino group of the spiro moiety in the analogues may be
responsible for a detrimental electrostatic interaction of the
spiro rings with the Glu-B138 of RT [53].
Fig. (6). Structures of 3'-spiro modified-TSAO analogues.
Several sugar-modified 3'-spiro-TSAO derivatives
including allofuranosyl-TSAO analogues [54], compounds
bearing L-sugars [55] or with inverted configuration at the C-
4' stereocenter [56] were also prepared. However, none of
these sugar modified TSAO compounds showed marked
antiviral efficacy (EC50 >10 m M).
Metabolism and Pharmacokinetics of TSAO Derivatives
The cellular uptake, metabolism and pharmacokinetic
properties of the N-3-methyl-substituted TSAO-T derivative
TSAO-m3T were investigated [57]. The compound is very
stable in physiological solutions (i.e. PBS pH 7.2) at room
temperature and no intracellular metabolites (besides the
parent compound) were detected in at least three different
human cell lines upon prolonged exposure of the cells to the
compound. Uptake of TSAO-m3T by human CEM cells is
drug concentration-dependent and increased proportionally
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with increasing initial extracellular TSAO- m3T
concentrations up to 20 m g/mL. Within 6 hr of incubation,
the cells were almost completely saturated with the test
compound. Further incubation up to 72 hr did not markedly
increase the intracellular concentration of the compound.
The pronounced lipophilicity of TSAO-m3T (partition
coefficient in octanol/water: >>20) is most likely responsible
for the rapid uptake of the compound into human T-
lymphocytes. No intracellular metabolic conversion of
TSAO-m3T was observed in CEM, MT-4 or MOLT-4 cells.
In contrast to the lack of metabolism of TSAO-m3T in cell
cultures, the compound seems to be metabolized in vivo.
Upon intravenous bolus administration of the compound to
mice at 0.75 mg/kg, TSAO-m3T was rapidly cleared from the
plasma in a mono-exponential manner (half-life: 22 min;
distribution volume: 9.5 L/kg; total body clearance: 17.8
L/hr/kg) [57].
TSAO-m3T mainly accumulated in the lungs, followed
by the heart, kidney and liver. The reason for the preferential
accumulation of the compound in the lungs is still unclear. In
view of the neurological disorders associated with AIDS, it
is important to note that the brain contains low but
significant levels of TSAO-m3T. Although TSAO-m3T levels
in the brain are low, they may suffice to achieve a
therapeutic effect since TSAO-m3T was found to be
antivirally effective at a 50% inhibitory concentration as low
as 30 ng/ mL [34a, 58]. Thus, our data indicate that TSAO-
m3T is able to cross the blood-brain barrier, and thus may be
able to inhibit virus replication in the brain compartment.
Significant amounts of different metabolites of TSAO-
m3T were detected in most tissues, the liver, kidney and
spleen being the organs that showed the most extensive
metabolism. The principal metabolites identified were
TSAO-m3T derivatives in which the t-butyldimethylsilyl
moiety at O-2' and/or O-5' had been split-off. The free base
N3-methylthymine was not detected [58].
Resistance Development of HIV-1 Against TSAO
Compounds
One of the major problems of the NNRTIs is the rapid
emergence of virus drug resistance [59]. HIV-1 resistance to
NNRTIs is primarily asociated with mutations in the HIV-1
RT gene usually located between codons 98 and 108,
between codons 179 and 190 and between codons 225 and
236 [60]. All these mutations are lining the lipophilic
NNRTI-specific binding pocket in the p66 subunit of the RT.
In cell culture, TSAO derivatives rapidly select for
TSAO-resistant HIV-1 strains. All TSAO-resistant HIV-1
strains sequenced (more than 20) contain one amino acid
change at position 138 of their RT [39]. In all cases glutamic
acid was invariably replaced by lysine. This mutation
consistently occurs regardless of the TSAO congener used
for selection [40a]. No other mutations have ever been found
in the sequenced domain of the RT gene of the TSAO-
resistant HIV-1 strains obtained in cell culture. The
Glu138Lys RT mutant HIV-1 strains are highly resistant to
TSAO inhibition, but they retain marked to full sensitivity to
most other NNRTIs, as well as to nucleoside RT inhibitors
(NRTIs) and to the acyclic nucleoside phosphonates [39,
40b, 61, 62]. This provides direct evidence that 138-Glu
must play a crucial role in the recognition of TSAO
derivatives by the enzyme.
By site-directed mutagenesis we demonstrated that this
glutamic acid residue at position 138 of the p51 subunit, but
not of the p66 subunit of HIV-1 RT, determines the
sensitivity and resistance of the enzyme to the inhibitory
effects of the TSAO derivatives [51]. So far, no other HIV-1-
specific inhibitors are reported to preferentially select for
HIV-1 strains that are mutated at that position.
Although TSAO derivatives do not seem to select for
mutant HIV-1 strains containing amino acid changes at
Tyr181Cys, Tyr188Cys and Val106Ala in their RT, they
considerably lose activity against such mutant HIV-1 strains,
while retaining substantial activity agains Leu100Ile and
Lys103Asn mutants [63]. These data strongly suggest the
presence of additional interaction points between the TSAO
molecules and the p66 RT subunit (that may serve either as
direct interaction sites for the TSAO compounds or at least
help in maintaining the desirable conformation of the TSAO
binding site in the RT heterodimer). TSAO compounds are
the only molecules within the group of NNRTIs for which
aminoacids at both HIV-1 RT subunits (p66 and p51) are
needed for optimal interaction with the enzyme.
Site-directed Mutagenesis Studies of HIV-1 RT at Amino
Acid Position 138
Although the Glu138 amino acid is highly conserved in
HIV-1 strains, recently, the presence of the Glu138Ala
mutation in several samples of drug-treated but TSAO-
inexperienced patients has been reported [64]. This
Glu138Ala RT mutated virus also showed a decreased
sensitivity to TSAO derivatives.
In a study we sought to address the question why the
Glu138Lys RT mutation invariably appeared under TSAO
selective pressure [65]. Seven RT mutants (i.e., Ala, Asp,
Gln, Gly, Lys, Phe, and Tyr) at position 138 were
constructed by site-directed mutagenesis. The mutant
Glu138Asp, Glu138Lys, Glu138Gln, Glu138Ala, and
Glu138Gly RTs retained marked catalytic activity. In
contrast, the Glu138Phe and Glu138Tyr RT mutants showed
poor RNA-dependent DNA polymerase activity (30 and 4%
of wild-type, respectively). TSAO derivatives lost their
inhibitory activity against all mutant enzymes, except against
the closely related Glu138Asp RT mutant that remained as
sensitive to TSAOs as did wild-type RT. Other NNRTIs,
including delavirdine, emivirine, and the thiocarboxanilide
UC-781, and the NRTI ddGTP retained pronounced
inhibitory activity against all mutant enzymes (Table 1).
When the amino acid mutations at position 138 of RT were
introduced in recombinant virus clones, the sensitivity/
resistance spectrum obtained toward the TSAOs and other
NNRTIs was similar to those observed for the isolated
recombinant mutant enzymes (Table 2). The Glu138Lys RT
mutant virus had the most marked resistance to TSAOs,
followed by the Glu138Gln, Glu138Phe, Glu138Gly,
Glu138Tyr, and Glu138Ala virus mutants. The Glu138Asp
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RT mutant virus kept full sensitivity to the TSAO
derivatives. Mixtures of Glu138Lys RT mutant virus with
the other virus clones mutated at the 138 position resulted in
all cases, except for the Glu138Asp and Glu138Gly RT
mutant viruses, in an outgrowth of the Glu138Lys RT mutant
virus. Among the Glu138 RT mutants investigated, the
Glu138Lys RT proved most resistant to TSAO derivatives. It
also was among the most catalytically efficient enzymes,
compared with the majority of the mutants made, and
resulted in highly replication-competent virus. Moreover, the
G ® A transition mutation that is necessary to create the
mutated Glu138Lys codon is known to occur preferentially
and more easily than other base changes. Those three
findings may explain why the Glu138Lys RT mutant virus
strains but not virus strains containing other amino acids at
position 138 invariably emerge in cell cultures under TSAO
drug pressure.
Effect of dNTP Pool Imbalances on Resistance
Development Against TSAO Derivatives
The RNA genome of the lentivirus human
immunodeficiency virus type 1 (HIV-1) is significantly
richer in adenine nucleotides than the statistically equal
distribution of the four different nucleotides that is expected
[66, 67]. This compositional bias may be due to the guanine-
to-adenine (G ® A) nucleotide hypermutability of the HIV
genome, which has been explained by dCTP/dTTP pool
imbalances during reverse transcription [68]. The adenine
nucleotide bias together with the poor fidelity of HIV-1
reverse transcriptase markedly enhances the genetic variation
of HIV and may be responsible for the rapid emergence of
drug-resistant HIV-1 strains. In 1998 Balzarini and co-
workers [69] hypothesized that the low fidelity of HIV-1 RT
on the one hand, and the adenine nucleotide hypermutability
bias on the other hand, could be exploited to manipulate and
Table 1. Sensitivity of HlV-l Wild-Type G1u138 and Mutant Recombinant RTs to the inhibitory Effects of NNRTIs and ddGTP.
IC50 ( m M)a
Compound Glu138
(Wild Type)
Glu138Asp Glu138Ala Glu138Lys Glu138Gln Glu138Gly Glu138Tyr Glu138Phe
TSAO-T 2.5 ± 0.6 1.5 ± 0.2 77 ± 8 >850 >85 >850 >850 >85
TSAO-m3T 0.9 ± 0.2 0.7 ± 0.1 81 ± 4 >83 >830 >83 >83 >830
TSAO-triaz. 23 ± 7 12 ± 4 >90 >90 >90 >90 >90 >900
Delavirdine 0.39 ± 0.05 0.5 ± 0.2 2.1 ± 0.1 1.8 ± 0.3 1.0 ± 0.8 1.4 ± 1.2 0.34 ± 0.02 0.3 ± 0.00
Emivirine 0.1 ± 0.05 0.1 ± 0.1 0.47 ± 0.03 3 ± 1 0.5 ± 0.1 0.5 ± 0.2 0.39 ± 0.02 0.57 ± 0.02
UC-781 0.03 ± 0.00 0.05 ± 0.02  0.2 ± 0.1 0.2 ± 0.1 0.15 ± 0.08 0.31 ± 0.02 0.06 ± 0.00 0.28 ± 0.02
ddGTP 0.07 ± 0.01 0.05 ± 0.03 0.09 ± 0.04 0.02 ± 0.00 0.02 ± 0.00 0.10 ± 0.02 0.14 + 0.01 0.10 ± 0.01
a  IC 50, or 50% inhibitory concentration required to inhibit the enzyme activity by 50%, using poly(rC) • o1igo(dG) as the template-primer and [2.8-
3H]dGTP as the radiolabeled
substrate. The IC 50 was determined using E. coli extracts as the source of the wild-type and mutant RTs. For the G1u138Phe mutant RT purified enzyme was used because E. coli
extract did not show sufficient activity. The data are means of two to three independent experiments (means ± SD).
Table 2. Sensitivity of HlV-l Wi1d-Type G1u138 and Mutant Recombinant Strains to NNRTIs and ddG in CEM Cell
Cultures.
EC50 ( m M) for recombinant mutant HIV-1 strainsa
Compound Glu138
(Wild Type)
Glu138Asp Glu138Ala Glu138Lys Glu138Gln Glu138Gly Glu138Tyr Glu138Phe
TSAO-T 0.024±0.015 0.013±0.004 0.52±0.19 >3 2.1±1.4 0.76±0.48 0.53±0.38 2.5±1.6
TSAO-m3T 0.035±0.019 0.021±0.018 0.41±0.09 >17 12±7 1.2±0.7 0.34±0.24 11±7
Delavirdine 0.008±0.007 0.009±0.006 0.07±0.04 0.05±0.02 0.04±0.03 0.02±0.01 0.007±0.003 0.004±0.001
Emivirine 0.0021±0.0016 0.0018±0.0009 0.023±0.008 0.042±0.023 0.011±0.004 0.006±0.0034 0.0043±0.0019 0.0044±0.0019
UC-781 0.0009±0.0003 0.0013±0.0006 0.009±0.006 0.010±0.0033 0.007±0.007 0.005±0.002 0.0013±0.0001 0.002±0.001
Efavirenz 0.003±0.002 0.0015±0.0003 0.005±0.001 0.0041±0.0001 0.007±0.002 0.003±0.001 0.0014±0.0001 0.0013±0.0003
ddG 3±2 4±3 11±8 4±1 5±2 6±4 3±2 1.6±0.3
a EC50, or 50% Effective concentration, or compound concentration required to inhibit HIV-1-induced cytopathicity in CEM cell cultures by 50%. The data are means of at least four
to six two independent experiments (means ± SD).
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redirect the mutational pattern of resistance of HIV-1 to
antiviral drugs by influencing the dNTP pools of the target
cells. To provide experimental evidence for this novel
concept, TSAO derivatives (i.e. TSAO-m3T and TSAO-5-
dimethylamino-1,2,3-triazole) were used. It was shown that
it is possible to shift the appearance of the TSAO-
characteristic Glu138Lys (AAG codon) RT mutation to a
Glu138Gly (GGG) RT mutation under TSAO-m3T or
TSAO-triazole drug pressure when the ratio of cellular
endogenous dCTP/ dTTP pools is increased in the presence
of exogenous dCyd [69]. However, the G ® A transition
mutation that occurs in the Glu138 codon (GAG) when
converted to the Glu138Lys codon (AAG) is known as a
favorable hypermutation that may preferentially and more
easily occur than any other base changes [particularly the
opposite A® G transition mutation [68c] that takes place
when the Glu138 codon (GAG) is converted to the
Glu138Gly codon (GGG) under elevated dCTP/dTTP levels
[69]. This consideration raises the possibility that increasing
the dCTP/dTTP ratio may be of long-term therapeutic
benefit, which represents an interesting issue for further
exploration. It would not be unlikely that this phenomenon
may also contribute to the predominant appearance of the
Glu138Lys RT mutation but not the Glu138Gly RT mutation
in cell culture.
From the above study it was concluded that it is possible
to counteract the mutational bias and particularly the
adenine-over-guanine nucleotide preference of HIV-1 by
changing the endogenous dNTP pool levels/ratios in HIV-1-
infected cells by using antimetabolic drugs. Forcing the virus
to change its inherent nucleotide bias may lead to better
control of viral drug resistance development.
Combination of TSAO Compounds and NNRTIs and
NRTIs in HIV-1 Infected Cell Cultures
From a therapeutical point of view, the development of
resistance is one of the major milestones in the treatment of
AIDS patients. It is now widely accepted that the best
strategy to fight against resistance is the use of combination
therapy. It has been proposed that a rational approach toward
drug combination may be based on the choice of drugs that
do not select for mutations resulting in cross-resistance of the
virus for the combined drugs [70].
TSAO derivatives have been used in several double and
triple drug combination studies with both NNRTIs [e.g.
thiocarboxanilides (UC), BHAP U-88204 and U-90152,
TIBO R82913, Nevirapine (BI-RG-587) and emivirine
(MKC-442), etc] and NRTIs lamivudine (3TC) [63, 71, 72].
When 3TC, TSAO-m3T and the thiocarboxanilide UC10
were used individually, they rapidly led to the emergence of
drug-resistant HIV-1 mutants (Glu138Lys for TSAO-m3T,
Met184Val for 3TC, and Lys103Thr/Asn for UC10) in cell
culture [63, 71, 72]. When 3TC was combined with either
TSAO-m3T or UC10 or UC42, emergence of drug-resistant
virus was markedly delayed or even fully suppresed. The
concomitant presence of the Glu138Lys and Met184Val
mutations was noted in the RT of these mutant viruses that
emerged under combination therapy of 3TC with either
TSAO-m3T or UC10, but the UC10 resistance mutation
Lys103Thr/Asn was no longer detected, which may mean
that it must have been suppressed upon combining UC10
with 3TC [63]. It was found that combination of TSAO-m3T,
UC10 or UC42 with 3TC resulted in marked potentiation of
the anti-HIV-1 activity and suppress virus breakthrough in
cell culture at compound concentrations that were ³  1-2
orders of magnitude lower than when the drugs were used
individually [63, 71, 72]. Triple-drug combinations
containing 3TC plus TSAOm3T and BHAP and MKC-442
further potentiate the suppressive effect of the double
combinations on HIV replication, and indeed resulted in
complete suppression of virus breakthrough in HIV-1-
infected CEM cell cultures at drug concentrations that
readily allowed virus replication when the single drugs were
administered as "monotherapy". Similar results were
observed when BHAP U-88204 was added to the
combination of UC42 with TSAO-m3T [71].
TSAO Compounds in "Knocking-out" Studies
It has been proposed that an approach to prevent
emergence of resistant virus (and apparent clearance of the
virus from the culture) would be the use of "knocking-out"
concentrations of the HIV-1-specific inhibitors (NNRTIs)
[8a, 73]. When added to the HIV-1-infected cell cultures
from the start of the infection at sufficiently high
concentrations, the compounds may completely suppress
virus replication and thus prevent the virus from becoming
resistant. At a concentration of 2.5 m g/ml, TSAO-m3T
suppress virus breakthrough ("knock out" the virus) for 10 to
15 days, although this represents a shorther time period than
that observed with other NNRTIs. The "knocking-out"
principle also holds for HIV-1 RT mutant strains. Thus in
cell cultures infected with the TSAO-resistant Glu138Lys
mutant, virus replication could be completely suppressed by
micromolar concentrations of NNRTIs (i.e., TIBO, BHAP,
nevirapine) [74]. Interestingly, the concentrations required to
knock out the virus can be significantly reduced when well-
defined combinations of NNRTIs or combinations of
NNRTIs with AZT or 3TC are used. For example when
TSAO-m3T (0.4 m g/ml) and 3TC (0.05-0.1 m g/ml) were
combined, they were able to prevent virus breakthrough for
more than 52 days. However, when used individually at the
same concentrations they could not prevent virus
breakthrough for more than a few days. Similar effects have
been reported with two NNRTIs (i.e., TSAO-m3T and
thiocarboxanilide UC42). When combined, virus
breakthrough could be suppressed for more than 77 days at
drug concentrations (0.1 m g/ml for UC42 and 1 m g/ml for
TSAO-m3T) at which the individual compounds delayed
virus breakthrough for only 20 and 25 days, respectively
[71]. Virus breakthrough could be suppressed for even
longer, and at lower drug concentrations, if a third NNRTI
(BHAP) was added to the combination of UC42 with TSAO-
m3T, which points to the feasibility of triple drug
combinations in preventing virus breakthrough and resis-
tance development [71].
TSAO-T as Part of Potential Multifunctional Inhibitors
of HIV-1 RT
Heterodimers [TSAO-T]-[NRTI]
It was suggested that an approach to combination therapy
would be the use of dimers resulting from the linking of a
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NNRTI and a NRTI through an appropriate spacer, in an
attempt to combine the inhibitory capacity of these two
different classes of molecules [30, 31]. Due to the NNRTI,
the dimers might be highly specific to HIV-1 RT and due to
the presence of the NRTI, the dimers might lower the speed
of emergence of virus-drug resistance. It has been
demonstrated that the binding of the NNRTIs to the HIV-1
RT results in an even tighter binding of the natural substrates
(dNTPs) to the enzyme [33]. This cooperative interaction
between the substrate (dNTP)-binding site and the non-
substrate (NNRTI)-binding site may be interpreted as
indicative of a synergistic action between the NNRTIs and
ddNTPs. The interaction between the two binding sites may
provide a means to increase the effectiveness of different
drugs when combined, or of a single drug when combining
the functionalities of a non-nucleoside RT Inhibitor (NNRTI)
and a 2',3'-dideoxynucleoside or an acyclic nucleoside
phosphonate RT inhibitor (NRTI) [33].
Crystallographic studies revealed that the NRTI binding
site and the NNRTI binding pocket are close enough (»  10-
19Å) [30] to be reached by one single molecule that
combines in its structure the functionalities of both kinds of
inhibitors. With this aim, and in an attempt to combine the
HIV-inhibitory capacity of NRTI analogues and NNRTIs we
reported, in 1995, for the first time the synthesis and anti-
HIV-activity of a series of heterodimers of the general
formula [NRTI]-(CH2)n-[NNRTI] [75]. The heterodimers
had in their structure a NRTI such as AZT combined with a
NNRTI such as TSAO-T or HEPT, linked through an
appropriate spacer between the N-3 of the thymine base of
both compounds. As spacer, we used aliphatic chains of
different lenghts in order to obtain a heterodimer possessing
an optimum distance between both active principles (NRTI
and NNRTI) "Fig. (7)". The [TSAO-T]-(CH2)n-[AZT]
heterodimers proved markedly inhibitory to HIV-1.
However, they were less potent inhibitors than the parent
compounds from which they were derived [75]. Also, if AZT
was replaced by thymidine in the heterodimer molecules,
potent anti-HIV-1 activity was observed. However, the
corresponding [HEPT]-(CH2)n-[AZT] dimers were inactive.
The best compound in the series of prepared compounds was
the [TSAO-T]-(CH2)3-[AZT] heterodimer (EC50: 0.38±0.07
m M) "Fig. (7)". None of the dimers were endowed with anti-
HIV-2 activity.
To obtain better insights in the feasibility of this
heterodimer approach and to increase the inhibitory efficacy
of the test compounds against HIV-1 RT, novel analogues of
the [AZT]-(CH2)3-[TSAO-T] prototype were prepared "Fig.
(7)". In these novel series, other NRTIs such as d4T, and an
expanded range of linkers with different conformational
freedom and nature were synthesized [76]. Other attachment
sites for these linkers on the base part of the NRTI analogue
were explored, by anchoring the linker at the C-5 position of
the thymine of the NRTI and at the N-3 position of the
thymine base of TSAO-T. Moreover, in order to circumvent
the dependence of the NRTI moiety of the heterodimer on
activation by cellular nucleoside kinases, novel heterodimers
in which the NRTI contained a masked monophosphate
group (phosphoramidate) at the 5'-position were also
prepared. Among the novel heterodimers, several derivatives
showed potent anti-HIV-1 activity, which proved
comparable, or even superior, to that of the AZT heterodimer
prototype. The nature of the NRTI was important for the
anti-HIV-1 activity. In particular, the d4T heterodimer
derivative containing a propyl linker between the N-3
positions of the thymine bases of TSAO-T and d4T (18) was
5- to 10- fold more inhibitory to HIV-1 (EC50: 0.018±0.03
m M) than the corresponding AZT heterodimer prototype and
even 2-fold more potent than the unsubstituted TSAO-T
parent compound. In general the nature of the spacer and the
position of the linker on the NRTI could be changed while
keeping the antiviral activity. The phosphoramidate series of
compounds had no improved anti-HIV-1 activity over the
corresponding non-phosphorylated analogues. Intriguingly,
Fig. (7). Examples of [TSAO-T]—(CH2)n—[NRTIs] heterodimers.
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the phosphoramidate heterodimer (19) (containing d4T as the
nucleoside) had marginal, but significant, anti-HIV-2 activity
(EC50: 15 m M), whereas the corresponding AZT derivative
had not.
TSAO Bidentate Inhibitors
A series of TSAO derivatives that contained groups with
bivalent ion-chelating properties were also prepared [77].
The design of such molecules was based on the reported
measurable interaction between the inhibitors binding pocket
(NNRTIs) and the Mg2+ binding site [33]. It was proposed
that attaching an NNRTI to molecules that should bind
specifically to the nearby metal ion-binding site might create
bidentate inhibitors with a stronger affinity, even for mutant
enzyme forms. The TSAO derivatives prepared combine in
their structure the functionality of a NNRTI (TSAO-T) and a
metal chelating moiety (a b -diketone group and enol-ether
groups) linked by an appropriate spacer (polymethylene
linkers of different lengths) "Fig. (8)" at the N-3 position of
the thymine [78, 79]. Some of the new compounds preserved
their anti-HIV-1 activity (EC50: 0.06-0.97 m M) being
comparable to that of the parent compound TSAO-T, but
display a markedly increased antiviral selectivity (SI21: 2170;
SI20: 1250 vs SITSAO-T: 233), owing to lower cytotoxicity
(CC50: ³  130->250 m M) [77].
Hybrids [TSAO-T]-[Foscarnet]
In vitro combination experiments of TSAO-m3T with
Foscarnet (PFA, a potent inhibitor of the TSAO-
characteristic HIV-1 RT/138 Lys mutant) [27] "Fig. (8)"
resulted in a very pronounced suppression of virus
replication and related virus breakthrough in the CEM cell
cultures. However, foscarnet shows poor penetration into
cells due to its polyanionic nature at physiological pH. These
findings led us to prepare "hybrids" that combine TSAO
derivatives and foscarnet in a single molecule through a
labile covalent ester bond (22) "Fig. (8)" [80]. The major
consideration in the design of these hybrids was to explore
whether the highly lipophilic TSAO molecule may serve as
driving-force of PFA into the cells thus resulting in an
improvement of cell membrane permeability of the latter.
The [TSAO-T]-[PFA] conjugate may also escape
extracellular hydrolysis and once inside the cell would
liberate the parent compounds. Therefore, we prepared
[TSAO-T]-[PFA] conjugates containing the parent drugs
linked via ester bonds to permit hydrolytic cleavage at
physiological pH, or enzyme-mediated catalysis. Several
[TSAO-T]-[PFA] conjugates proved markedly inhibitory to
HIV-1 (EC50: 0.47-0.82 m M) and also showed moderate
activity against TSAO-resistant (EC50: 20-50 m M) and PFA-
resistant (EC50: 0.16 m M) HIV-1 strains. Compounds were
stable in PBS and in human serum. The conjugate (22)
regenerated the parent compounds in CEM cell extracts.
Molecular Model of Interaction of TSAO-T with HIV-1
RT
Despite the similar binding geometry observed for
several chemically diverse NNRTIs in their complexes with
HIV-1 RT, considerable variation exists in the non-
nucleoside binding pocket of the enzyme [17, 81]. Co-
crystallization attempts of HIV-1 RT with TSAO derivatives
have been unsuccessful so far. As already mentioned, the
HIV-1 resistance to TSAO compounds is determined by the
Fig. (8). Examples of TSAO-bidentated inhibitors and [TSAO-T]—[PFA] conjugates.
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Glu138Lys mutation (in the b7 - b 8 loop of the p51 subunit)
[40a, 51]. Recently, it has been shown that TSAO-T and its
N3-ethyl derivative (TSAO-e3T) destabilize the p66/p51
HIV-1 RT heterodimer and the p66/p66 homodimer in a
concentration-dependent manner leading to a loss in their
ability to bind DNA [20, 82]. However, TSAO-e3T was
unable to destabilize the subunit interactions of the
Glu138Lys mutant enzyme. These results strongly suggest a
binding mode for TSAO that may substantially deviate from
that of other non-nucleoside RT inhibitors.
A preliminary molecular model of the HIV-1 RT-TSAO
complex placed TSAO-T near the interface between the p66
and p51subunits with most of the molecule inside the
standard NNRTI binding pocket in p66 [41a, 48, 49]. This
model located the essential 5'-TBDMS substituent of TSAO-
T into the cavity formed by Tyr181, Tyr188 and Trp229 and
placed the thymine ring close to Tyr318, with substituents on
the N3 position pointing toward a channel connecting the
binding pocket with the solvent. In this orientation, the spiro
amino group was able to form a good hydrogen bond with
the carboxyl group of Glu138 in the p51 subunit, and this
important interaction was thought to lie at the origin of the
Glu138Lys mutation detected under the selective pressure of
TSAO derivatives. Despite the relative success of this model
in accounting for many experimental findings, some data
argued against it. For the purpose of validation, we designed
modifications on both the inhibitor and the enzyme. On the
one hand, it was inferred from the model that removal of the
O4 oxygen of the pyrimidine ring in TSAO-T would lead to
an increase in binding affinity, since the negative
electrostatic potential generated in this region of the inhibitor
was detrimental for binding as this oxygen was close to the
main chain carbonyl group of His-A235. However the TSAO
compound (23) "Fig. (9)", resulting from the removal of the
oxygen atom from position 4 of the thymine ring in the
prototype compound, resulted in a partial loss of activity
rather than in the expected increment (EC50, 23: 0.23 m M vs
EC50,TSAO-T: 0.05 m M) [83]. On the other hand, the model
suggested that mutation of Arg172 to Ala would decrease the
affinity for TSAO compounds but would not affect the
binding of other NNRTIs, because the negative electrostatic
potential generated by the solvent-exposed sulfone group of
TSAO could give rise to a favorable interaction energy with
the positively charged side chain of Arg172 (or Lys172 in
other HIV-1 strains). However, again, the experimental
results did not corroborate the molecular model. Instead,
replacement of the arginine at position 172 by an alanine in
RT led to an unanticipated improvement in the inhibitory
activity of TSAO analogues [83]. Undoubtedly, our early
model of interaction was strongly biased by attempts to make
use of the NNRTI binding pocket, as seen in many
complexes solved by X-ray crystallography. This led us to
explore alternative binding modes and to study the energetics
of dimerization and the rationale for the effects of TSAO-T
on RT dimer stabilization [83]. The docking strategy
consisted of extending the putative binding site further away
from the standard NNRTI binding pocket and using all the
reported X-ray crystal structures of the enzyme, both
complexed with other inhibitors and in the apo form, as input
for an automated docking program. This led us to propose a
novel binding mode for TSAO-m3T that is quite distinct
from that of "classical" NNRTIs [83, 84]. In the updated
model, TSAO-m3T straddles between subunits binding at the
p66/p51 interface but it does not make use of the NNRTI
binding pocket.
Fig. (9). Base modified TSAO compounds.
According to the updated molecular model, TSAO-m3T
binds at the interface between the two subunits "Fig. (10)" in
such a way that the strong dipole moment of the spiro group
( m  = 8.4 debye) [53] is properly aligned in the field created
by the positive electrostatic region emanating from Lys101
and Lys103 in the p66 subunit and the negatively charged
Glu138 in the p51 subunit. This Glu138 is at hydrogen bond
distance of the 4"-amino of the spiro group of TSAO-m3T.
An additional polar interaction (hydrogen bond) is formed
between the O4 of the thymine ring and the hydroxyl group
of Thr139 in the p51 subunit (which explains why removal
of this O4 is detrimental to activity). The remaining
stabilizing interactions are hydrophobic and exploit two
cavities present at the enzyme interface that provide binding
pockets for the 2'- and 5'-TBDMS substituents of TSAO
derivatives. In the p51 subunit, the side chains of Ile31,
Val35, and the hydrocarbon side chains of Lys32 and Ser134
provide a large hydrophobic surface that accomodates the
indispensable 5'-TBDMS substituent. In the p66 subunit, the
hydrophobic pocket is made up mainly by Pro176 and
Val179, both of which interact with the 2'-TBDMS group.
The new molecular model is in agreement with the
biochemical evidence and with known structure-activity and
mutagenesis data for this class of inhibitors including a
R172A mutant that had not been described previously. The
feasibility of the proposed binding mode was assessed by
analyzing the results of nanosecond MD simulations for the
complexes of TSAO-m3T with reduced models of the wild-
type and Arg172Ala mutant RT enzymes in the presence of
water molecules. The cost of desolvating the side chain of
this arginine residue was shown to be unfavorable for
complex formation, and this is suggested to be the main
reason accounting for the unanticipated improved binding of
TSAO-m3T to the Arg172Ala mutant enzyme.
According to the docking model, additional interactions
at or near the p51/p66 interface could result in compounds
with improved binding affinity over the prototype TSAO-T.
In the light of the present model, the N3 substituents of
TSAO derivatives would be found running parallel to the
subunit interface and mostly exposed to the solvent. A
structure-based modification on the lead compound TSAO-T
N
N
O
S O OSi
SiO
O O
H3C
O
H2N
NH
N
O
S O OSi
SiO
O O
H3C
O
H2 N
O
(CH2)3—OH
23 24
956    Current Topics in Medicinal Chemistry,  2004, Vol. 4, No. 9 Camarasa et al.
consisting of introducing a -(CH2)3-OH substituent in the
thymine N3 atom (compound 24 ) "Fig. (9)" resulted in a
2–6 fold better inhibitor, consistent with the prediction that
an additional hydrogen bond could be formed with the
carbonyl group of Pro140. This putative extra hydrogen bond
with the protein backbone may be partially offset by the
inherent flexibility of the methylene linker and by
competition with surrounding water molecules.
How do TSAO Derivatives exert Their Inhibitory Action?
With regard to the mechanism by which TSAO
derivatives exert their inhibitory action, it has been suggested
that the presence of the drug at the interface between the two
subunits may perturb the dynamics of subunit association
and/or prevent the conformational changes necessary for
loading the p66 subunit on to the template-primer. In fact, it
has been demonstrated that the heterodimeric enzyme shows
a reduced DNA binding ability in the presence of 5-fold
molar excess of TSAO-T and also that TSAO-e3T can induce
the dissociation of RT into inactive monomers under certain
experimental conditions. By studying the residues that are
involved in dimer formation, we have identified the b 7-b 8
loop in the p51 subunit as an important component of the
dimerization interface [83]. Interestingly, Glu138, the
residue that is found mutated to Lys in TSAO-resistant
viruses, is located in this loop, and our results with the
Glu138Lys mutant enzyme are consistent with the
experimental results that this substitution drastically reduces
the affinity of TSAO derivatives and at the same time does
not lead to gross changes in dimerization binding energy.
Nevertheless, dissociation of the subunits does not appear to
take place in the absence of denaturant, and the
concentrations of TSAO-m3T that are necessary to produce
this effect are higher than those needed to display inhibitory
activity [20, 82].
For RT inhibition by classical NNRTIs it has been
suggested that the most dramatic change in the protein
relative to the apoenzyme is the concerted movement of
strands b 6,  b 9, and b 10, which contain the functional
aspartic acid residues (Asp110, Asp185, and Asp186) that
comprise part of the polymerase active site [32]. By
comparing our simulations of wild-type HIV-1 RT in the
presence and in the absence of bound TSAO-m3T, a similar
disorganization of the catalytic aspartates is apparent "Fig.
(10)" although it is achieved through a different mechanism
[83]. The b 7- b 8 loop remains essentially unchanged but the
“pulling” interaction of TSAO-m3T with Lys101 and Lys103
gives rise to changes in both the b 5 and b 6 strands. On the
other hand, the “pushing” interaction with Val179 and
Pro176 determines a displacement of the b 9 and b 10 strands
and the a -helix immediately preceding b 9. Although these
results should be viewed with caution, given the limitations
of the reduced models used, it is tempting to speculate that
the presence of TSAO at the subunit interface may preclude
Fig. (10). Putative binding site of TSAO-m 3T (shown as sticks with C atoms coloured in green, and enveloped in a semi-transparent van der
waals surface) at the interface between the p66 (Ca  trace in cyan) and p51 (C a  trace in pink) subunits. The side chains of Glu138, Tyr181,
Tyr188, Trp229 and the three catalytic aspartate residues are also displayed as sticks with C atoms coloured in grey.
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adoption of the catalytically active conformation by the
enzyme. In this dynamic context, the presence of additional
residues not directly in contact with the TSAO molecule
could be important in the inhibition mechanism as cross-
resistance to TSAO derivatives has been shown in virus
mutants selected by other NNRTIs, such as those involving
RT amino acid positions 106, 181 and 188, which are within
the "classical" NNRTI binding site [85].
The current model points to a well-defined part of the
dimerization interface as a novel target for inhibitor design
[83]. To our knowledge, TSAO-T is the first example of a
small non-peptidic molecule that can interfere with the
dimerization process and can thus be used as a lead
compound for the design of an entirely new family of RT
inhibitors that would act independently of both the active site
and the NNRTI binding pocket.
Exploring Dimerization of RT as a Mode of Inhibition of
the Enzyme. Towards "Second Generation" TSAO
Derivatives
TSAO-deaminated (4"-H-TSAO-T)
Based on the hypothesis, supported by our experimental
data and molecular modelling studies, that a specific
interaction exists between the Glu138 of the p51 subunit and
the 4"-amino group of the 3'-spiro moiety of the TSAO
molecules, we considered of interest to remove this amino
group and evaluate the effect of this modification on the
activity and resistance profile of the corresponding
deaminated TSAO derivative. Therefore, we synthesized the
first TSAO molecule that lacked the amino group at the 3'-
spiro moiety (25) "Fig. (11)" [86]. This compound kept HIV-
1 specificity (NNRTIs characteristic), it proved inhibitory to
HIV-1 replication in cell cultures (EC50 = 0.15-0.53 m M)
and was also inhibitory against HIV-1 RT (IC50 = 3.3 m M).
Moreover, it was devoid of any activity either against HIV-2
RT or HIV-2 replication. Compound 25 was able to select
for virus strains that proved to escape the drug pressure. The
virus strain that emerged under escalating drug pressure of
25 was used for sensitivity/resistance testing against a
variety of NNRTIs (including TSAO derivatives) and
NRTIs. This TSAO molecule showed an aberrant resistance
spectrum. Interestingly, this drug resistant strain kept full
sensitivity to all NRTI and NNRTIs, including TSAO
compounds that contain the NH2 group at the spiro moiety.
Resistance was observed only against the deaminated TSAO
derivative 25 in the presence of which it was selected. Even
more intriguing is the observation that the drug also lost
inhibitory potential against virus mutants that contain certain
NNRTIs specific mutations in the reverse transcriptase. The
latter observations point to an interaction with the NNRTI
pocket of the RT. However, when sequencing the RT gene of
the drug resistant virus strain, any of the well known
NNRTIs specific mutations in the RT gene including 138-
Lys (characteristic for TSAO resistance) were not detected.
Fig. (11).
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It is still unclear whether a mutation has appeared
downstream of the region where the NNRTI mutations are
located (i. e. RNAseH domain). So, the deaminated TSAO
derivative represents a new type of molecule with HIV-1
specificity, but most likely with another mechanism of action
than that of the classical NNRTIs.
TSAO Compounds Modified at the N-3 Position
In the light of the updated molecular model of interaction
of TSAO derivatives with HIV-1 RT, the N-3 substituents of
the pyrimidine ring would run parallel to the subunit
(p66/p51) interface [83]. Structure-base modifications were
introduced in the prototype compound (TSAO-T) in order to
get compounds with additional interactions with aminoacids
at/or near the p51-p66 interface [87]. Several N-3-substituted
TSAO derivatives were prepared. These novel TSAO
analogues contained different functional groups that might
give additional interaction with one or more aminoacids of
the dimer interface and thus might disrupt crucial interface
interactions "Fig. (11)". Thus, compounds having at the N-3
position functional groups of different nature (alkyl, aryl,
acid, ester, amido, ether, halogen, alcohol, amino, etc.),
linked to this position through flexible polymethylene linkers
of different lenght (n = 1-4), were prepared [87]. Compounds
with restricted conformational flexibility in the linker were
also prepared by introduction of cis or trans double bonds.
All the compounds synthesized showed pronounced activity
against HIV-1 replication (EC50 = 0.02-0.76 m M) while
being inactive against HIV-2 [82]. The N-3 methylcarbo-
xamide TSAO compound (26) proved 2-6 fold more active
than the prototype TSAO-T and did not show toxicity, thus
being the most selective TSAO derivative prepared so far
(Selectivity index CC50/EC50: 10000).
3"-Substituted TSAO Derivatives
Following with the rational of preparing TSAO
compounds that may give additional interactions with
aminoacids at/or near the p51-p66 interface, next we focused
our attention on modifications of the 3'-spiro moiety of
TSAO derivatives. According to the molecular model of
interaction of TSAO derivatives with HIV-1 RT, this moiety
represents the closest part of the molecule to the interface
between the p51 and p66 subunit domains, in fact it is buried
in the subunit interface [83]. Based on this hypothesis, we
introduced different functional groups at position 3'' of the
spiro ring of the prototype compound (TSAO-T) and its N-3
methyl derivative (TSAO-m3T) that may give additional
interactions with aminoacids adjacent to the Glu138 of the
p51 subunit [88]. Thus, several 3"-substituted TSAO
derivatives carrying differently substituted halogen, alkenyl,
alkynyl, allyl, aromatic and heteroaromatic groups were
prepared "Fig. (11)". In these novel analogues, the 4''-amino
group of the sultone spiro moiety was maintained to allow
the crucial interaction of TSAO derivatives with the Glu138
of the p51 subunit of the HIV-1 RT. The compounds
synthesized were evaluated for their inhibitoty effect on
HIV-1 and HIV-2 replication in cell culture. The
introduction of a bromine and particularly an iodine at the
3"-position (27) conferred the highest anti-HIV-1 activity
(EC50: 0.05 ± 0.03 m M) being comparable to that of the
prototype compound TSAO-T. In contrast, the presence at
this position of (un)substituted vinyl, alkynyl, phenyl or
thienyl groups markedly diminished the anti-HIV-1 activity
(EC50,27: 0.98-4.0 m M). Surprisingly, several of the 3”-
alkenyl substituted TSAO derivatives (28, "Fig. (11)")
gained also anti-HIV-2 activity at subtoxic concentrations
(EC50: 1.2-7.3 m M), an observation that is very unusual for
NNRTIs including TSAO derivatives. The structure-activity
relationship to have both anti-HIV-1 and anti-HIV-2 activity
in the TSAO molecules is currently unclear. When the
compounds were evaluated on their inhibitory activity
against recombinant HIV-2 RT, they were found to be
inactive at 500 m M. In addition, the most active anti-HIV-2
compounds were also inactive (> 500 µM) against a mutant
HIV-1 RT that contains the TSAO-characteristic Glu138Lys
resistance mutation. Taken together, the data point to a
different mechanism of action of some of the 3”-substituted
TSAO derivatives. The NNRTI (SJ-3366) has been reported
to inhibit both HIV-1 and HIV-2 replication, and to inhibit
HIV-1 RT but not HIV-2 RT [89]. This compound was
found to interfere with entry of HIV as a second mechanism
of action. Investigations on the mechanism of action of the
TSAO derivatives against HIV-2 is currently ongoing but
initial data may suggest that they seem to interfere with
cellular transcription rather than virus entry.
4"-Substituted TSAO Compounds
Finally, we focused on "second generation" TSAO
molecules directed against TSAO-resistant strains. We
prepared TSAO compounds bearing at the 4" position of the
spiro moiety different carbonyl functionalities (including
keto, carboxylic acid, ester, amide and urea groups) that may
interfere, by hydrogen bond formation, with the amino group
of Lys138 in TSAO-resistant HIV-1 strains [90]. The N-acyl
derivatives bearing oxalyl substituents at 4" position (29,
"Fig. (11)") showed potent activity against HIV-1 replication
(EC50 = 0.03-0.06 m M) while being inactive against HIV-2.
Moreover, the TSAO compound bearing a free carboxylic
acid residue (29, R = OH) shows moderate activity (IC50: 20-
50 m M) against mutant Lys138 HIV-1 RT (TSAO-
characteristic resistance mutation). From the biological
results it seems that the presence of two neighbouring
carbonyl groups at the 4" position of the spiro moiety is
important for activity against both HIV-1 wild type and HIV-
1 TSAO-resistant viruses. Recently it has been found that the
b  carbonyl group (not directly attached to the 4"-amino
group), seems to be important for the activity of these
compounds since either monocarbonyl TSAO derivatives or
non-neighbouring dicarbonyl TSAO compounds (i.e. ureido
derivatives etc) were devoid of antiviral activity (EC50,: 0.6
m M vs >50 m M).
CONCLUSIONS
In this review we have tried to gather and summarize the
work developed in our laboratories, during the last twelve
years, that led to the discovery and study of a unique class of
specific inhibitors of HIV-1 reverse transcriptase, the TSAO
family of compounds.
Since the discovery of TSAO-T, more than 500
derivatives have been prepared and evaluated against HIV-1
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and HIV-2 replication in cell culture and HIV-1 RT. Due to
the high degree of functionalization, the presence of
stereogenic centres and the presence of both acid and base
sensitive groups, in these nucleosidic molecules, their
synthesis has been a real challenge. It has not always been
straightforward, and it has required the development of mild
and stereoselective synthetic procedures, especially in those
TSAO-derivatives modified in the spiro moiety (an
aminospirooxathioledioxide, previously unknown and first
described by us [91]).
Since our initial reports in 1992 on the first TSAO
compounds and their specific inhibition of HIV-1 RT, the
structure of these "aberrant" nucleosides has been the subject
of many questions. Why do these nucleosides behave as
NNRTIs?; Why is the presence of the tert-butyldimethylsilyl
moiety mostly at 5'-position so crucial for activity?; Why, if
they behave as NNRTIs, do they not share the typical
"butterfly" three dimensional structure characteristic for
many NNRTIs?; Why do they always and consistently select
for the Glu138Lys mutation, that is not described with any
other NNRTI?.
During these twelve years we have tried to address and
solve some of these questions, and some of the answers are
contained in this review. In this process, we have found new
features that may allow the clasification of TSAO
compounds as a unique class of HIV-1 RT inhibitors.
Besides their highly functionalized nucleoside structure,
TSAO compounds are among the very few HIV-1 RT
inhibitors for which aminoacids at both subunits of RT are
needed for optimal interaction. Moreover, they are the first
small molecules that seem to interfere with the dimerization
process of the enzyme, which suggests a new and different
mechanism of inhibition of HIV-1 RT with regards to the
other known NNRTIs. Finally, because dimerization of HIV-
RT is a prerequisite for enzymatic activity, interference with
the dimerization process could constitute an alternative
strategy for RT inhibition. Based on our biological results
and on the molecular model of interaction, we believe that
with the TSAO molecule, we have now an important tool in
hand to rationally design potent dimerization inhibitors.
ACKNOWLEDGEMENTS
We are grateful to all the students that have participated
in the different projects directed to the development of
TSAO derivatives. The work here presented has been
supported by grants from the Spanish CICYT, the
Comunidad de Madrid and grants from the European
Commission, the NATO and by the René Descartes Award-
2001.
REFERENCES
[1] (a) Kinchington, D.; Gee, S.; Balzarini, J.; Gait, M.; de Clercq, E.
Current antiviral agents FactFile: 1999-2000 update. Part II –
Human immunodeficiency viruses. Int. Antiviral News 2000, 8, 4-
21. (b) Ba1zarini, J.; De Clercq, E. Biochemica1 pharmacology. A.
Nucleoside and nonnucleoside reverse transcriptase inhibitors
active against HIV. In Merigan, T.C.; Bartlett, J.G.; Bolognesi, D.
(Eds.), Textbook of AIDS Medicine Ch. 47 (pp. 815-847).
Philadelphia: Williams & Wilkins. 1998.
[2] (a) Tavel, J.A.; Miller, K.D.; Masur, H. Guide to major clinical
trials of antiretroviral therapy in human immunodeficiency virus-
infected patients: protease inhibitors, non-nucleoside reverse
transcriptase inhibitors, and nucleotide reverse transcriptase
inhibitors. Clin. Infect. Dis. 1999, 28, 643-676. (b) Ba1zarini, J.;
and De Clercq, E. Biochemica1 pharmacology of analogs active
against HIV. In T. C. Merigan, J. G. Bartlett, & S. Broder (Eds.),
Textbook of AIDS Medicine Ch. 49 (pp. 751-772). Philadelphia:
Williams & Wilkins. 1994. (c) De Clercq, E. New perspectives for
the treatment of HIV infections. N. Trends Mediterranean J. Infect.
Parasit. Dis. 1998, 13, 7-20.
[3] (a) De Clercq, E. Antiviral drugs: current state of the art. J. Clin.
Virol. 2001, 22, 73-89. (b) De Clercq, E. New perspectives for the
treatment of HIV infections. Verh K Acad Geneesk Belg. 1998, 60,
13-45.
[4] Schinazi, R.F. Competitive inhibitors of human immunodeficiency
virus reverse transcriptase. Perspect. Drug Discov. Des. 1993, 1,
151-180.
[5] De Clercq, E. Towards improved anti-HIV chemotherapy:
therapeutic strategies for intervention with HIV infections. J. Med.
Chem. 1995, 38, 2491-2517.
[6] Young, S.D. Nonnucleoside inhibitors of HIV-1 reverse
transcriptase. Perspect. Drug Discov. Des. 1993, 1, 181-192.
[7] De Clercq, E. HIV-1 specific RT inhibitors: Highly selective
inhibitors of human immunodeficiency virus type 1 that are
specifically targeted at the viral reverse transcriptase. Med. Res.
Rev. 1993, 13, 229-258.
[8] (a) De Clercq, E. Non-nucleoside reverse transcriptase inhibitors
(NNRTIs) for the treatment of human immunodeficiency virus type
1 (HIV-1) infections: strategies to overcome drug resistance
development. Med. Res. Rev.  1996, 16, 125-157. (b) De Clercq, E.
The role of non-nucleoside reverse transcriptase inhibitors
(NNRTIs) in the therapy of HIV-1 infection. Antiviral Res. 1998,
38, 153-179.
[9] (a) Fuzeon brand enfuvirtide (T-20). http://www.aidsmeds.com/
drugs/T-20.htm. (b) Lalezari, J.P.; Henry, K.; O'Hearn, M.;
Montaner, J.S.; Piliero, P.J.; Trottier, B.; Walmsley, S.; Cohen, C.;
Kuritzkes, D.R.; Eron, J.J. Jr; Chung, J.; DeMasi, R.; Donatacci, L.;
Drobnes, C.; Delehanty, J.; Salgo, M. Enfuvirtide, an HIV-1 fusion
inhibitor, for drug-resistant HIV infection in north and south
america. N. Engl. J. Med. 2003, 348, 2175-2185.
[10] (a) De Clercq, E. New developments in anti-HIV chemotherapy.
Biochim. Biophys. Acta 2002, 1587, 258-275. (b) LaBranche, C.C.;
Galasso, G.; Moore, J.P.; Bolognesi, D.P.; Hirsch, M.S.; Hammer,
S.M. HIV fusion and its inhibition. Antiviral Res. 2001, 50, 95-115.
[11] (a) Butera, S.T. Therapeutic targeting of human immunodeficiency
virus type-l latency: current clinical realities and future scientific
possibilities. Antiviral Res. 2000, 48, 143-176. (b) Gulik, R.M.
New antiretroviral drugs . Clin. Microbiol. Infect.  2003, 9, 186-193.
(c) Cooley, L.A.; Lewin, S.R. HIV-1 cell entry and advances in
viral entry inhibitor therapy. J. Clin. Virol. 2003, 26, 121-132.
[12] Katz, R.A.; Skalka, A.M. The retroviral enzymes. Annu. Rev.
Biochem. 1994, 63 133-173.
[13] Vaishnav, Y.N.; Wong-Staal, F. The biochemistry of AIDS. Annu.
Rev. Biochem. 1991, 60, 577-630.
 [14] Basu, A.; Basu, S.; Modak, M. J. Structure-activity analyses of
HIV-1 reverse transcriptase. Biochem. Biophys. Res. Commun.
1992, 183, 1131-1138.
[15] (a) Rodgers, D.W.; Gamblin, S.J.; Harris, B.A.; Ray, S.; Culp, J.S.;
Hellmig, B.; Woolf, D.J.; Debouck, C.; Harrison, S.C. The
structure of unliganded reverse transcriptase from the human
immunodeficiency virus type 1. Proc. Natl. Acad. Sci. U. S. A.
1995, 92, 1222-1226. (b) Hsiou, Y.; Ding, J.; Das, K.; Clark, A.D.
Jr.; Hughes, S.H.; Arnold, E. Structure of unliganded HIV-1
reverse transcriptase at 2.7 Å resolution: implications of
conformational changes for polymerization and inhibition
mechanisms. Structure 1996, 4, 853-860.
[16] (a) Jacobo-Molina, A.; Ding, J.; Nanni, R.G.; Clark, A.D. Jr.; Lu,
X.; Tantillo, C.; Williams, R.L.; Kamer, G.; Ferris, A.L.; Clark, P.;
Hizi, A.; Hughes, S. H.; Arnold, E. Crystal structure of human
immunodeficiency virus type 1 reverse transcriptase complexed
with double-stranded DNA at 3.0 Å resolution shows bent DNA.
Proc. Natl. Acad. Sci. U. S. A . 1993, 90, 6320-6324. (b) Huang, H.;
Chopra, R.; Verdine, G.L.; Harrison, S.C. Structure of a covalently
trapped catalytic complex of HIV-1 reverse transcriptase:
implications for drug resistance. Science 1998, 282, 1669-1675.
960    Current Topics in Medicinal Chemistry,  2004, Vol. 4, No. 9 Camarasa et al.
[17] Ren, J.; Esnouf, R.; Garman, E.; Somers, D.; Ross, C.; Kirby, I.;
Keeling, J.; Darby, G.; Jones, Y.; Stuart, D.; Stammers, D. High
resolution structures of HIV-1 RT from four RT-inhibitor
complexes. Nature Struct. Biol. 1995, 2, 293-302.
[18] Wang, J.; Smerdon, S.J.; Jager, J.; Kohlstaedt, L.A.; Rice, P.A.;
Friedman, J.M.; Steitz, T.A. Structural basis of asymmetry in the
human immunodeficiency virus type 1 reverse transcriptase
heterodimer. Proc. Natl. Acad. Sci. U. S. A. 1994, 91, 7242-7246.
[19] Amacker, M.; and Hübscher, U. Chimeric HIV-1 and feline
immuno-deficiency virus reverse transcriptases: critical role of the
p51 subunit in the structural integrity of heterodimeric lentiviral
DNA polymerases. J. Mol. Biol. 1998, 278, 757-765.
[20] Harris, D.; Lee, R.; Misra, H.S.; Pandey, P.K.; Pandey, V.N. The
p51 subunit of human immunodeficiency virus type 1 reverse
transcriptase is essential in loading the p66 subunit on the template
primer. Biochemistry 1998, 37, 5903-5908.
[21] Rattner, L.; Haseltine, W.; Patarca, R.; Livak, K.W.; Starcich, B.;
Josephs, S.F.; Doran, E.R.; Rafalski, J.A.; Whitehorn, E.A.;
Baumeister, K.; Ivanoff, L.; Petteway Jr, S.R.; Pearson, M.L.;
Lautenberg, J.A.; Papas, T.S.; Ghrayeb, J.; Chang, N.T.; Gallo,
R.C.; Wong-Staal, F. Complete nucleotide sequence of the AIDS
virus, HTLV-III. Nature 1985, 313, 277-284.
[22] Pelletier, H.; Sawaya, M.A.; Kumar, A.; Wilson, S.H.; Krant, J.
Structures of ternary complexes of rat DNA polymerase b , a DNA
template-primer, and ddCTP. Science 1994, 264, 1891-1893.
[23] Steitz, T.A. DNA and RNA-dependent DNA polymerases. Current
Opinion in Structural Biology 1993, 3, 31-38.
[24] (a) Restle, T.; Müller, B.; and Goody, R.S. Dimerization of human
immunodeficiency virus type 1 reverse transcriptase. A target for
chemotherapeutic intervention. J. Biol. Chem. 1990, 265, 8986-
8988. (b) Müller, B.; Rest1e, T.; Weiss, S.; Gautel, M.; Sczakie1,
G.; Goody, R.S. Co-expression of the subunits of the heterodimer
of HIV-1 reverse transcriptase in Escherichia coli . J. Biol. Chem,
1989, 264, 13975-13978. (c) Rest1e, T.; Müller, B.; Goody, R.S.
RNase H activity of HIV reverse transcriptases is confined
exclusively to the dimeric forms. FEBS Lett. 1992, 300, 97-100. (d)
Morris, M.C.; Berducon, C.; Mery, J.; Heitz, F.; Divita, G. The
thumb domain of the p51-subunit is essential for activation of HIV
reverse transcriptase. Biochemistry 1999, 38, 15097-15103.
[25] Divita, G.; Restle, T.; Goody, R.S. Characterization of the
dimerization process of HIV-1 reverse transcriptase heterodimer
using intrinsic protein fluorescence. FEBS Lett. 1993, 324, 153-
158.
[26] Divita, G.; Rittinger, K.; Geourjon, C.; Deléage, G.; Goody, R.S.
Dimerization kinetics of HIV-1 and HIV-2 reverse transcriptase: a
two step process. J. Mol. Biol. 1995, 245, 508-521.
[27] Balzarini, J.; De Clercq E. Analysis of inhibition of retroviral
reverse transcriptase. Methods Enzymol 1996, 275, 472-502.
[28] (a) Fridland, A. Tenofovir, Gilead Sciences Inc. Curr. Opin. Anti-
infect. Invest. Drugs. 2000, 2, 295-301. (b) De Clercq, E. New
developments in anti-HIV chemotherapy. Current Medicinal
Chemistry 2001, 8, 1543-1572.
[29] Tantillo, C.; Ding, J.; Jacobo-Molina, A.; Nanni, R. G.; Boyer,
P.L.; Hughes, S. H.; Pauwels, R.; Andries, K.; Janssen, P.A.J.;
Arnold, E. Locations of anti-AIDS drug binding sites and
resistance mutations in the three-dimensional structure of HIV-1
reverse transcriptase. Implications for mechanisms of drug
inhibition and resistance. J. Mol. Biol. 1994, 243, 369-387.
[30] Nanni, R.G.; Ding, J.; Jacobo-Molina, A.; Hughes, S.H.; Arnold, E.
Review of HIV-1 reverse transcriptase three-dimensional structure:
Implications for drug design. Perspect. Drug Discov. Des. 1993, 1,
129-150.
[31] Smerdon, S.J.; Jäger, J.; Wang, J.; Kohlstaedt, L.A.; Chirino, A.J.;
Friedman, J. M.; Rice, P.A.; Steitz, T.A. Structure of the binding
site for non-nucleoside inhibitors of the reverse transcriptase of
human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA
1994, 91, 3911-3915.
 [32] Esnouf, R.; Ren, J.; Ross, C.; Jones, Y.; Stammers, D.; Stuart, D.
Mechanism of inhibition of HIV-1 reverse transcriptase by non-
nucleoside inhibitors. Nature Struct. Biol. 1995, 2, 302-308.
[33] Spence, R.A.; Kati, W.M.; Anderson, K.S.; Johnson, K.A.
Mechanism of inhibition of HIV -1 reverse transcriptase by non-
nucleoside inhibitors. Science 1995, 267, 988-993.
[34] (a) Balzarini, J.; Pérez-Pérez, M.J.; San-Félix, A.; Schols, D.;
Perno, C.F.; Vandamme, A.M.; Camarasa, M.J.; De Clercq, E.
2',5'- Bis - O - (tert-butyldimethylsilyl) - 3'-spiro - 5"-(4"- amino-1",2"-
oxathiole-2",2-dioxide) pyrimidine (TSAO) nucleoside analogues:
Highly selective inhibitors of human immunodeficiency virus type
1 that are targeted at the viral reverse transcriptase. Proc. Natl.
Acad. Sci. USA 1992, 89, 4392-4396. (b) Camarasa, M.J.; Pérez-
Pérez, M. J.; San-Félix, A.; Balzarini, J.; De Clercq, E. 3'-
Spironucleosides a new class of specific human immunodeficiency
virus type 1 inhibitors: Synthesis and antiviral activity of [2',5'-bis-
O-(tert-butyldimethylsilyl)-b -D-xylo and ribofuranose]-3'-spiro-5"-
[4" -  amino - 1", 2" - oxathiole - 2", 2" - dioxide] (TSAO) pyrimidine
nucleosides. J. Med. Chem. 1992, 35, 2721-2727.
[35] Balzarini, J.; Pérez-Pérez, M-J.; San-Félix, A.; Velázquez, S.;
Camarasa, M.J.; De Clercq, E. [2',5'-Bis-O-(tert-butyldi-
methylsilyl)]-3'-spiro-5"-(4"-amino-1",2"-oxathiole-2",2"-dioxide)
(TSAO) derivarives of purine and pyrimidine nucleosides as potent
and selective inhibitors of human immunodeficiency virus type 1.
Antimicrob. Agents Chemother. 1992, 36, 1073-1080.
[36] (a) Pérez-Pérez, M.J.; San-Félix, A; Balzarini, J.; De Clercq, E.;
Camarasa, M.J. TSAO Analogues. Stereospecific synthesis and
anti-HIV-1 activity of 1-[2',5'-bis-O-(tert-butyldimethylsilyl)-
b  - D-ribofuranosyl] - 3' - spiro - (5"-(4"-amino-1",2"-oxathiole-2",2"-
dioxide) pyrimidine and pyrimidine-modified nucleosides. J. Med.
Chem. 1992, 35, 2988-2995. (b) Pérez-Pérez, M.J.; San-Félix, A.;
Camarasa, M.J.; Balzarini, J.; De Clercq, E. Synthesis of [1-
[2',5'-bis-O-(t-butyldimethylsilyl)-b -D-xylo- and b -D-ribofuranosyl]
thymine] - 3' - spiro - 5" - [4" - amino - 1", 2" - oxathiole - 2", 2" -dioxide]
(TSAO). A novel type of specific anti-HIV agents. Tetrahedron
Lett. 1992, 33, 3029-3032.
[37] (a) Balzarini, J.; Pérez-Pérez, M.J.; San-Félix, A.; Camarasa, M.J.;
Barr, P.J.; De Clercq, E. Interaction of human immunodeficiency
virus type 1 (HIV-1) reverse transcriptase with the novel HIV-1
specific nucleoside analogue 1-[2',5'-bis-O-(tert-butyldimethyl-
silyl) - b - D -  ribofuranosyl] - 3'  - spiro-5"-[4"-amino-1",2"-oxathiole-
2",2"-dioxide]thymine (TSAO-T). Arch. Int. Phys. Biochem.
Biophys. 1992, 100, B28. (b) Camarasa, M.J.; Pérez-Pérez, M.J.;
Velázquez, S.; San-Félix, A.; Alvarez, A.; Ingate, S.; Jimeno, M.L.;
Karlsson, A.; De Clercq, E.; Balzarini, J. TSAO derivatives: Highly
specific inhibitors of human immunodeficiency virus type-1 (HIV-
1) replication. Nucleosides Nucleotides 1995, 14, 585-594. (c)
Balzarini, J.; Camarasa, M.J.; Karlsson, A. TSAO derivatives:
Highly specific human immunodeficiency virus type 1 (HIV-1)
reverse transcriptase inhibitors. Drugs of the Future 1993, 18,
1043-1055.
[38] Balzarini, J.; Pérez-Pérez, M.J.; San-Félix, A.; Camarasa, M.J.;
Bathurst, I.C.; Barr, P.J.; De Clercq, E. Kinetics of inhibition of
human immunodeficiency virus type 1 (HIV-1) reverse trans-
criptase by the novel HIV-1 specific nucleoside analogue 2',5'-
bis-O-(t-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1",2"-oxathiole-
2",2"-dioxide) thymine (TSAO-T). J. Biol. Chem. 1992, 267,
11831-11838.
[39] Balzarini, J.; Karlsson, A.; Vandamme, A.M.; Pérez-Pérez, M.J.;
Zhang, H.; Vrang, L.; Oberg, B.; Backbro, K.; Unge, T.; San-Félix,
A.; Velázquez, S.; Camarasa, M. J.; De Clercq, E. Human immuno-
deficiency virus type 1 (HIV-1) strains selected for resistance
against the HIV-1-specific [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-
spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)]- b -D-pentofuran-
osyl (TSAO) nucleoside analogues retain sensitivity to HIV-1-
specific nonnucleoside inhibitors. Proc. Natl. Acad. Sci. USA  1993,
90, 6952-6956.
[40] (a) Balzarini, J.; Velázquez, S.; San-Félix, A.; Karlsson, A.; Pérez-
Pérez, M.J.; Camarasa, M.J.; De Clercq, E. The HIV-l-specific
TSAO-purine analogues show a resistance spectrum that is
different from that of the HIV-l-specific non-nucleoside analogues.
Mol. Pharmacol. 1993, 43, 109-114. (b) Balzarini, J.; Karlsson, A.;
Pérez-Pérez, M.J.; Vrang, L.; Walbers, J.; Zhang, H.; Öberg, B.;
Vandamme, A.M.; Camarasa, M.J.; De Clercq, E. HIV-l-specific
reverse transcriptase inhibitors show differential activity against
HIV-1 mutant strains containing different amino acid substitutions
in the reverse transcriptase. Virology 1993, 192, 246-253.
[41] (a) Camarasa, M.J.; San-Félix, A.; Pérez-Pérez, M.J.; Velázquez,
S.; Alvarez, R.; Chamorro, C.; Jimeno, M.L.; Pérez, C.; Gago, F.;
De Clercq, E.; Balzarini, J. HIV-1 specific reverse transcriptase
inhibitors: why are TSAO-nucleosides so unique?. J. Carbohyd.
Chem. 2000, 19, 451-469. (b) Camarasa, M.J.; Pérez-Pérez, M.J.;
Velázquez, S.; San-Félix, A, Alvarez, R.; Ingate, S.; Jimeno, M.L.;
TSAO Compounds Current Topics in Medicinal Chemistry,  2004, Vol. 4, No. 9     961
De Clercq, E.; Balzarini, J. An overview of TSAO-T derivatives, a
"peculiar" class of HIV-1 specific RT inhibitors. In Bentley, P.H.
and O'Hanlon, PJ (Eds). Antiinfectives. Recent advances in
chemistry and structure-activity relationships. Ch.18 (pp.259-268).
1997. The Royal Society of Chemistry.
 [42] Velázquez, S.; Jimeno, M.L.; Camarasa, M.J.; Balzarini, J.
Synthesis of [1-[3',5'-bis-O-(tert-butyldimethylsilyl)-b -D-arabino-
and -b -D  -  ribofuranosyl] cytosine] - 2'  -  spiro -  5" - [4"-amino-1",2"-
oxathiole-2",2"-dioxide]. Analogue of the highly specific anti-HIV-
1 agent TSAO-T. Tetrahedron, 1994, 50, 11013-11022.
[43] (a) Ingate, S.; Pérez-Pérez, M.J.; De Clercq, E.; Balzarini, J.;
Camarasa, M.J. Synthesis and anti-HIV-1 activity of novel TSAO-
T derivatives modified at the 2'- and 5'-positions of the sugar
moiety. Antiviral Res. 1995, 27, 281-299. (b) Chamorro, C.; Pérez-
Pérez, M.J.; Rodríguez-Barrios, F.; Gago, F.; De Clercq, E.;
Balzarini, J.; San-Félix, A.; Camarasa, M.J. Exploiting the role of
the 5'-position of TSAO-T. Synthesis and anti-HIV evaluation of
novel TSAO-T derivatives. Antiviral Res. 2001, 50, 207-222. (c)
San-Félix, A.; Chamorro, C.; Pérez-Pérez, M.J.; Velázquez, S.; De
Clercq, E.; Balzarini, J.; Camarasa, M.J. Synthesis of novel 5'-
substituted TSAO-T analogues with anti-HIV-1 activity. J.
Carbohydr. Chem. 2000, 19, 635-640.
[44] Velázquez, S.; San-Félix, A.; Pérez-Pérez, M.J.; Balzarini, J.; De
Clercq, E.; Camarasa, M.J. TSAO analogues. 3. Synthesis and anti-
HIV-1 activity of 2',5'-bis-O-(tert-butyldimethylsilyl)-b -D-ribofura-
nosyl-3'-spiro-5"-(4"-amino-1",2"-oxathiole-2",2"-dioxide) purine
and purine-modified nucleosides. J. Med. Chem. 1993, 36, 3230-
3239.
[45] San-Félix, A.; Velázquez, S.; Pérez-Pérez, M.J.; Balzarini, J.; De
Clercq, E.; Camarasa, M.J. Novel series of TSAO-T derivatives.
Synthesis and anti-HIV-1 activity of 4-, 5- and 6-substituted
pyrimidine analogues. J. Med. Chem. 1994, 37, 453-460.
[46] (a) Alvarez, R.; Velázquez, S.; San-Félix, A.; Aquaro, S.; De
Clercq, E.; Perno, C.F.; Karlsson, A.; Balzarini, J.; Camarasa,
M.J. 1,  2, 3 - Triazole  - [[2', 5'  -  bis - O - (tert-butyldimethylsilyl)-b -D-
ribofuranosyl]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)
(TSAO) analogues: Synthesis and anti-HIV-1 activity. J. Med.
Chem. 1994, 37, 4185-4194. (b) San-Félix, A.; Alvarez, R.;
Velázquez, S.; De Clercq, E.; Balzarini, J.; Camarasa, M.J.
Synthesis and anti-HIV-1 activity of 4- and 5-substituted 1,2,3-
triazole-TSAO derivatives. Nucleosides Nucleotides, 1995, 14,
595-598.
[47] Chamorro, C.; De Clercq, E.; Balzarni, J.; Camarasa, M.J.; San-
Félix, A. TSAO-T analogues bearing amino acids at position N-3
of thymine: synthesis and anti-human immunodeficiency virus
activity. Antiviral Chem. Chemother. 2000, 11, 61-69.
[48] Velázquez, S.; Alvarez, A.; Pérez, C.; Gago, F.; De Clercq, E.;
Balzarini, J.; Camarasa, M.J. Regiospecific synthesis and anti-
human immunodeficiency virus activity of novel 5-substituted N-
alkylcarbamoyl and N,N-dialkylcarbamoyl 1,2,3-triazole-TSAO
analogues. Antiviral Chem. Chemother. 1998, 9, 481-489.
[49] Velázquez, S.; Chamorro, C.; Pérez-Pérez, M.J.; Alvarez, R.;
Jimeno, M.L.; Martín-Domenech, A.; Pérez, C.; Gago, F.; de
Clercq, E.; Balzarini, J.; San-Félix, A.; Camarasa, M.J. Abasic
analogues of TSAO-T as the first sugar derivatives that specifically
inhibit HIV-1 reverse transcriptase. J. Med. Chem . 1998, 41, 4636-
4647.
[50] Balzarini, J.; Pérez-Pérez, M.J.; San-Félix, A.; Velázquez, S.;
Camarasa, M.J.; Vandamme, A.M.; Karlsson, A.; De Clercq, E.
TSAO Derivatives. A novel class of HIV-l-specific inhibitors.
Proceedings of the Third International Symposium on the chemical
synthesis of Antibiotics and Related Microbial Products, Kloster
Banz, Germany, September 20-25, 1992, In: Krohn K, Kirs H,
Maas RH, eds. Antibiotics and antiviral compounds, chemical
synthesis and modifications. 1993.
[51] (a) Jonckheere, H.; Taymans, J.M.; Balzarini, J.; Velázquez, S.;
Camarasa, M.J.; Desmyter, J.; De Clercq, E.; Anne, J. Resistance
of HIV-1 reverse transcriptase against [2',5'-bis-O-(tert-
butyldimethylsilyl)-3'-spiro-5''-(4''-amino-1'',2''- oxathiole-2'',2''-
dioxide)](TSAO) derivatives is determined by the mutation
Glu138 ® Lys on the p51 subunit. J. Biol. Chem. 1994, 269, 25255-
25258. (b) Boyer, P.L.; Ding, J.; Arnold, E.; Hughes, S.H. Subunit
specificity of mutations that confer resistance to nonnucleoside
inhibitors in human immunodeficiency virus type 1 reverse
transcriptase. Antimicrob. Agents Chemother. 1994, 38, 1909-1914.
[52] Alvarez, R.; Jimeno, M.L.; Pérez-Pérez, M.J.; De Clercq, E.;
Balzarini, J.; Camarasa, M.J. Synthesis and and anti-human
immunodeficiency virus type 1 activity of novel 3'-spiro nucleoside
analogues of TSAO-T. Antiviral Chem. Chemother. 1997, 8, 507-
517.
[53] Alvarez, R.; Jimeno, M.L.; Gago, F.; Balzarini, J.; Pérez-Pérez,
M.J.; Camarasa, M.J. Novel 3'-spiro nucleoside analogues of
TSAO-T. Part II. A comparative study based on NMR
conformational analysis in solution and theoretical calculations.
Antiviral Chem. Chemother. 1998, 9, 333-340.
[54] Alvarez, R.; San-Félix, A.; De Clercq, E.; Balzarini, J.; Camarasa,
M.J. Novel TSAO derivatives. Synthesis and anti-HIV-1 activity of
allofuranosyl-TSAO-T analogues. Nucleosides Nucleotides 1996,
15, 349-359.
[55] Ingate, S.; Camarasa, M.J.; De Clercq, E.; Balzarini, J. Synthesis
and anti-HIV-1 activity of [1-[2',5'-bis-O-(tert-butyldimethylsilyl)-
b -L-ribofuranosyl]thymine]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-
2'',2''-dioxide) (L-TSAO-T), the L-enantiomer of the highly specific
HIV-1 reverse transcriptase inhibitor TSAO-T. Antiviral Chem.
Chemother. 1995, 6, 365-370.
[56] Ingate, S.; De Clercq, E.; Balzarini, J.; Camarasa, M.J. Novel L-
lyxo and 5'-deoxy-5'-modified TSAO-T analogs: Synthesis and
anti-HIV-1 activity. Antiviral Res. 1996, 32, 149-164.
[57] Balzarini, J.; Naesens, L.; Bohman, C.; Pérez-Pérez, M.J.; San-
Félix, A.; Camarasa, M.J.; De Clercq, E. Metabolism and pharma-
cokinetics of the anti-HIV-1-specific inhibitor [1-[2',5'-bis-O-(tert-
butyldimethylsilyl) - b -D -  ribofuranosyl] -  3 -  N - methyl-thymine]-3'-
spiro - 5'' - (4'' - amino - 1'', 2''  - oxathiole - 2'', 2''-dioxide). Biochem.
Pharmacol. 1993, 46, 69-77.
[58] Pauwels, R.; Andries, K.; Debyser, Z; Van Daele, P.; Schols, D.;
Vandamme, A-M.; Stoffels, P.; De Vreese, K.; Woestenborghs, R.;
Janssen, C.G.M.; Anné, J.; Cauwenbergh, G.; Desmyter, J.;
Heykants, J.; Janssen, M.A.C.; De Clercq, E.; Janssen, P.A.J.
Potent and highly selective HIV-1 inhibition by a new series of a -
anilino phenyl acetamide (a -APA) derivatives targeted at HIV-l
reverse transcriptase. Proc. Natl. Acad. Sci. USA 1993, 90, 17l1-
1715.
[59] Vandamme, A-M.; Van Laethem, K.; De C1ercq, E. Managing re-
sistance to anti-HIV drugs. Drugs 1999, 57, 337-361.
[60] Schinazi, R.F.; Larder, B.A.; Mel1ors, J.W. Mutations in retroviral
genes associated with drug resistance. Int. Antiviral News 1999, 7,
46-69.
[61] Balzarini, J.; Karlsson, A.; Vandamme, A.M.; Pérez-Pérez, M.J.;
Zhang, H.; Vrang, L.; Öberg, B.; Backbro, K.; Unge, T.; San-Félix,
A.; Velázquez, S.; Camarasa, M. J.; De Clercq, E. Human immuno-
deficiency virus type 1 (HIV-1) strains selected for resistance
against the HIV-1-specific [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-
spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)]- b -D-pentofuran-
osyl (TSAO) nucleoside analogues retain sensitivity to HIV-1-
specific nonnucleoside inhibitors. Proc. Natl. Acad. Sci. U. S. A.
1993, 90, 6952-6956.
[62] (a) Balzarini, J.; Kleim, J.P.; Riess, G.; Camarasa, M.J.; De Clercq,
E.; Karlsson, A. Sensitivity of (138 Glu ® Lys) mutated human
immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT)
to HIV-1-specific RT inhibitors. Biochem. Biophys. Res. Commun.
1994, 201, 1305-1312. (b) Balzarini, J.; Karlsson, A.; Camarasa,
M.J.; De Clercq, E. HIV-1 strains selected for resistance against
one partcicular class of HIV-1-specific reverse transcriptase
inhibitors may retain sensitivity to other classes of HIV-1-specific
inhibitors. Int. Antivir. News, 1993, 1, 66-68.
[63] Balzarini, J.; Pelemans, H.; Pérez-Pérez, M.J.; San-Félix, A.;
Camarasa, M.J.; De Clercq, E., Karlsson, A. Marked inhibitory
activity of non-nucleoside reverse transcriptase inhibitors against
human immunodeficiency virus type 1 when combined with (-
)2',3'-dideoxy-3'-thiacytidine. Mol. Pharmacol. 1996, 49, 882-890.
[64] Van Laethem, K.; Schmit, J.-C.; Pelemans, H.; Balzarini, J.;
Witvrouw, M.; Pérez-Pérez, M.J.; Camarasa, M.J.; Esnouf, R.M.;
Aquaro, S.; Cenci, A.; Perno, C.F.; Hermans, P.; Sprecher, S.;
Ruiz, L.; Clotet, B.; Van Wijngaerden, E.; Van Ranst,
M.; Desmyter, J.; De Clercq, E.; Vandamme, A.-M. Presence of 2',
5' - bis - O -  (tert-butyldimethylsilyl) -  3'-spiro - 5'' -(4''-amino-1'',2''-
oxathiole-2'',2''-dioxide) (TSAO)-resistant virus strains in TSAO-
unexperienced HIV patients. AIDS Res. Hum. Retrovir. 2000, 16,
825-833.
962    Current Topics in Medicinal Chemistry,  2004, Vol. 4, No. 9 Camarasa et al.
 [65] Pelemans, H., Aertsen, A.; Van Laethem, K.; Vandamme, A-M.;
De Clercq, E.; Pérez-Pérez, M.J.; San-Félix, A.; Velázquez, S.;
Camarasa, M.J.; Balzarini, J. Site-Directed Mutagenesis of Human
Immunodeficiency Virus Type 1 Reverse Transcriptase at Amino
Acid Position 138. Virology 2001, 280, 97-105.
[66] (a) Berkhout, B.; van Hemert, F.J. The unusual nucleotide content
of the HIV RNA genome results in a biased amino acid
composition of HIV proteins Nucleic Acids Res. 1994, 22, 1705-
1711. (b) Bronson, E.C.; Anderson, J.N. Nucleotide composition as
a driving force in the evolution of retroviruses. J. Mol. Evol.  1994,
38, 506-532.
[67] (a) Keulen, W.; Boucher, C.; Berkhout, B. Nucleotide substitution
patterns can predict the requirements for drug-resistance of HIV-1
proteins Antivir. Res. 1996, 31, 45-57. (b) Keulen, W.; Back,
N.K.T.; van Wijk, A.; Boucher, C.; Berkhout, B. Initial appearance
of the 184Ile variant in lamivudine-treated patients is caused by the
mutational bias of human immunodeficiency virus type I reverse
transcriptase. J. Virol. 1997, 71, 3346-3350. (c) Myers, G. Tenth
anniversary perspectives on AIDS, HIV between past and future.
AIDS Res. Hum. Retrovir. 1994, 10, 1317-1324.
[68] (a) Martinez, M.A.; Vartanian, J.-P.; Wain-Hobson, S.
Hypermutagenesis of RNA using human immunodeficiency virus
type 1 reverse transcriptase and biased dNTP concentrations. Proc.
Natl. Acad. Sci. USA 1994, 91, 11787-11791. (b) Vartanian, J.-P.;
Meyerhans, A.; Asj, B.; Wain-Hobson, S. Selection, recom-
bination, and G® A hypermutation of human immunodeficiency
virus type 1 genomes. J. Virol. 1991, 65, 1779-1788. (c) Vartanian,
J.-P.; Meyerhans, A.; Sala, M.; Wain-Hobson, S. G ® A
hypermutation of the human immunodeficiency virus type 1
genome evidence for dCTP pool imbalance during reverse
transcription. Proc. Natl. Acad. Sci. USA 1994, 91, 3092-3096.
[69] (a) Balzarini, J.; Karlsson, A.; Velázquez, S.; Pérez-Pérez, M.J.;
San-Félix, A.; Alvarez, R.; Perno, C.F.; Hatse, S.; Esnouf, R.; De
Clecq, E.; Camarasa, M.J. Shifts in the endogenous 2'-
deoxynucleotide pools affect the selection of mutant HIV strains
resistant to non-nucleoside reverse transcriptase inhibitors. 2nd
International Workshop on HIV Drug Resistance and Treatment
Strategies, Lake Maggiore, Italy, June 24-27 (1998); Abstract 26.
(b) Balzarini, J.; Camarasa, M.J.; Pérez-Pérez, M.J.; San-Félix, A.;
Velázquez, S.; Perno, C.F.; De Clecq, E.; Anderson, J.N.; Karlsson,
A. Exploitation of the low fidelity of human immunodeficiency
virus type 1 (HIV -1) reverse transcriptase and the nucleotide
composition bias in the HIV-1 genome to alter the drug resistance
development of HIV. J. Virol. 2001, 75, 5772-5777.
[70] (a) Balzarini, J. Suppression of resistance to drugs targeted to
human immunodeficiency virus reverse transcriptase by
combination therapy. Biochem. Pharmacol. 1999, 58, 1-27. (b)
Pauwels, R.; Andries, K.; Desmyter, J.; Schols, D.; Kukla, M.J.;
Breslin, H.J.; Raeymaeckers, A.; Van Gelder, J.; Woestenborghs,
R.; Heykants, J.; Schellekens, K.; Janssen, M.A.C.; De Clercq, E.;
Janssen, P.A.J. Potent and selective inhibition of HIV-1 replication
in vitro by a novel series of TIBO derivatives. Nature 1990, 343,
470-474. (c) De Clercq E. HIV resistance to reverse transcriptase
inhibitors. Biochem. Pharmacol. 1994, 47, 155-169.
[71] Balzarini, J.; Pérez-Pérez, M.J.; Velázquez, S.; San-Félix, A.;
Camarasa, M.J.; De Clercq, E.; Karlsson, A. Suppression of the
breakthrough of human immunodeficiency virus type 1 (HIV-1) in
cell culture by the thiocarboxanilide derivatives when used
individually or in combination with other HIV-1-specific inhibitors
(i.e. TSAO derivatives). Proc. Natl. Acad. Sci. USA 1995, 92,
5470-5474.
[72] Balzarini, J.; Karlsson, A.; Pérez-Pérez, M.J.; Camarasa, M.J.;
Tarpley, W.G.; De Clercq E. Treatment of Human
immunodeficiency virus type 1 (HIV-1)-infected cells with
combinations of HIV-1-specific inhibitors results in a different
resistance pattern than does treatment with single-drug therapy. J.
Virol. 1993, 67, 5353-5359.
 [73] Balzarini, J.; Karlsson, A.; Pérez-Pérez, M.J.; Camarasa, M.J.; De
Clercq E. Knocking-out concentrations of HIV-1-specific inhibitors
completely suppress HIV-1 infection and prevent the emergence of
drug-resistant virus. Virology 1993, 196, 576-585.
[74] Balzarini, J.; Karlsson, A.; Sardana, V.V.; Emini, E.A.; Camarasa,
M.J.; De Clercq E. Human immunodeficiency virus 1 (HIV-1)-
specific reverse transcriptase (RT) inhibitors may suppress the
replication of specific drug-resistant (E138K)RT HIV-1 mutants or
select for highly resistant (Y181C® C181I)RT HIV-1 mutants.
Proc. Natl. Acad. Sci. USA 1994, 91, 6599-6603.
[75] Velázquez, S.; Alvarez, R.; San-Félix, A.; Jimeno, M.L.; De
Clercq, E.; Balzarini, J.; Camarasa, M.J. Synthesis and Anti-HIV
activity of [AZT]-[TSAO-T]and [AZT-[HEPT]dimers as potential
multifunctional inhibitors of HIV-1 reverse transcriptase. J. Med.
Chem. 1995, 38, 1641-1649.
[76] Velázquez, S.; Tuñón, V.; Jimeno, M.L.; Chamorro, C.; De Clercq,
E.; Balzarini, J.; Camarasa, M.J. Potential multi-functional
inhibitors of HIV-1 reverse transcriptase. Novel [AZT]-[TSAO-
T]and [d4T]-[TSAO-T]heterodimers modified in the linker and in
the dideoxynucleoside region. J. Med. Chem. 1999, 42, 5188-5196.
[77] Chamorro, C.; Camarasa, M.J.; Pérez-Pérez, M.J.; De Clercq, E.;
Balzarini, J.; San-Félix, A. An approach towards the synthesis of
potential metal-chelating TSAO-T derivatives as bidentate
inhibitors of human immunodeficiency virus type 1 reverse
transcriptase. Antivir. Chem. Chemother. 1998, 9, 413-423.
[78] Martell & Calvin. Chelate stability constants. In Chemistry of the
Metal Chelate Compounds. Edited by Prentice-Hall, INC. New
York: pp. 514-561 (1953).
[79] Perrin, D.D. Stability constants of metal-ion complexes: part B
Organic ligands. In IUPAC Chemical Data Series. nº 22. Oxford:
Pergamon Press (pp 273-280 and 1019-1020). 1979.
[80] Velázquez, S.; Lobatón, E.; De Clercq, E.; Balzarini, J.; Camarasa,
M.J. "Double-drugs" [TSAO-T]–[PFA]. The first conjugate of
foscarnet with a non-nucleoside reverse transcriptase inhibitor
through a labile covalent esther bond. 15th International Conference
on Antiviral Research. Prague, Czech Republic, March 17-21
(2002); Abstract 24.
 [81] (a) Hopkins, A.L.; Ren, J.; Esnouf, R.; Willcox, B.E.; Jones, E.Y.;
Ross, C.; Miyasaka, T.; Walker, R.T.; Tanaka, H.; Stammers, D.K.;
and Stuart, D.I. Complexes of HIV-1 reverse transcriptase with
inhibitors of the HEPT series reveal conformational changes
relevant to the design of potent non-nucleoside inhibitors. J. Med.
Chem. 1996, 39, 1589-1600. (b) Esnouf, R.M.; Ren, J.; Hopkins,
A.L.; Ross, C.K.; Jones, E. Y.; Stammers, D.K.; Stuart D.I. Unique
features in the structure of the complex between HIV-1 reverse
transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152
explain resistance mutations for this nonnucleoside inhibitor. Proc.
Natl. Acad. Sci. USA 1997, 94, 3984-3989.
[82] Sluis-Cremer, N.; Dmitrienko, G.I.; Balzarini, J.; Camarasa, M.J.;
Parniak, M.A. Human immunodeficiency virus type 1 reverse
transcriptase dimer destabilization by 1-[Spiro[4"-amino-2",2"-
dioxo-1",2"-oxathiole-5",3'-[2',5'-bis-O-(tert-butyldimethylsilyl)-b -
D-ribofuranosyl]]]-3-ethylthymine. Biochemistry 2000, 39, 1427-
1433.
[83] Rodríguez-Barrios, F.; Pérez, C.; Lobatón, E.; Velázquez, S.;
Chamorro, C.; San-Félix, A.; Pérez-Pérez, M.J.; Camarasa, M.J.;
Pelemans, H.; Balzarini, J.;Gago, F. Identification of a putative
binding site for [2', 5' -  Bis - O - (tert - butyldimethylsilyl) - b  - D -
ribofuranosyl] - 3' - spiro - 5" - (4" - amino - 1", 2" - oxathiole - 2", 2"-
dioxide) thymine (TSAO) derivatives at the p51-p66 interface of
HIV-1 reverse transcriptase. J. Med. Chem. 2001, 44, 1853-1865.
[84] Arion, D.; Fletcher, R.S.; Borkow, G.; Camarasa, M.J.; Balzarini,
J.; Dmitrienko, G.I.; Parniak, M.A. Differences in the inhibition of
human immunodeficiency virus type 1 reverse transcriptase DNA
polymerase activity by analogs of nevirapine and [2',5'-bis-O-(tert-
butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1",2"-oxathiole-2",2"-
dioxide](TSAO). Mol. Pharmacol. 1996, 50, 1057-1064.
[85] Balzarini, J.; Karlsson, A.; De Clercq, E. Human immuno-
deficiency virus type 1 drug-resistance patterns with different
1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives.
Mol. Pharmacol. 1993, 44, 694-701.
[86] (a) Lobatón, E.; Velázquez, S.; San-Félix, A.; De Clercq, E.;
Balzarini, J.; Camarasa, M.J. 4"-H-TSAO-T a novel prototype in
the HIV-1 specific TSAO family. Nucleosides Nucleotides Nucleic
Acids 2001, 20, 711-714. (b) Velázquez, S.; Lobatón, E.; Pérez-
Pérez, M.J.; De Clercq, E.; Balzarini, J.; Camarasa, M.J. 4th
International Workshop on Drug Resistance and Treatment
Strategies. Sitges, Spain, June 12-16 (2000); Abstract 10.
[87] Bonache, M.C.; Chamorro, C.; Velázquez, S.; De Clercq, E.;
Balzarini, J.; Camarasa, M.J.; San-Félix, A. N-3 substituted TSAO
derivatives as a probe to explore the dimeric interface of HIV-1
reverse transcriptase. Nucleosides Nucleotides Nucleic Acids 2003,
22, 947-949.
TSAO Compounds Current Topics in Medicinal Chemistry,  2004, Vol. 4, No. 9     963
[88] Lobatón, E.; Rodríguez-Barrios, F.; Gago, F.; Pérez-Pérez, M.J.;
De Clercq, E.; Balzarini, J.; Camarasa, M.J.; Velázquez, S.
Synthesis of 3"-substituted TSAO_derivatives with anti-HIV-1 and
anti-HIV-2 activity through an efficient palladium-catalyzed cross-
coupling approach. J. Med. Chem. 2002, 45, 3934-3945.
[89] Buckheit, R.W. Jr.; Watson, K.; Fliakas-Boltz, V.; Russell, J.;
Loftus, T.L.; Osterling, M.C.; Turpin, J.A.; Pallansch, L.A.; White,
E.L.; Lee, J.-W.; Lee, S.-H; Oh, J.-W.; Kwon, H.-S.; Chung, S.-G.;
Cho, E.-H. SJ-3366, a unique and highly potent nonnucleoside
reverse transcriptase inhibitor of human immunodeficiency virus
type 1 (HIV-1) that also inhibits HIV-2. Antimicrob. Agents
Chemother. 2001, 45, 393-400.
[90] Lobatón, E.; Velázquez, S.; Pérez-Pérez, M.J.; Jimeno, M.L.; San-
Félix, A.; De Clercq, E.; Balzarini, J.; Camarasa, M.J. "Second
generation" of TSAO compounds directed against HIV-1 TSAO-
resistant strains. Nucleosides Nucleotides Nucleic Acids 2001, 20,
707-710.
[91] (a) Calvo-Mateo, A.; Camarasa, M.J.; Díaz-Ortiz, A.; De las Heras,
F.G. Novel aldol-type cyclocondensation of O-mesyl-
(methylsulphonyl)-cyanohydrins. Application to the stereospecific
synthesis of branched-chain sugars. J. Chem. Soc., Chem. Commun.
1988, 1114-1115. (b) Pérez-Pérez, M.J.; Camarasa, M.J.; Díaz-
Ortiz, A.; San-Félix, A.; De las Heras, F.G. Stereospecific synthesis
of branched-chain sugars by a novel aldol-type cyclocondensation.
Carbohydr. Res. 1991, 216, 399-411.

